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1ABSTRACT
Mice infected with different strains of Corynelbacterium
Parvum (C. Parvum) affected their ability to produce tumour
necrosis factor (TNF) in the ser urn after challenged with
lipopolysacchar ide (LPS). TNF could be produced from mice primed
with C. Parvum or Listeria monocytogenes and then challenged with
LPS. C. Parvum strain CN 6134 was a better priming agent than C._
Parvum strain 4182 since the former could produce higher TNF
titre. Though C. Parvum strain 4182 could produce one tenth of
TNF as compared with that of strain 6134, mice primed with strain
4182 were less susceptible to endotoxin shock.
The rate of mortality from endotoxin shock was high in
mice in the course of the production of TNF. Administradtion of
the non-steroidal anti-inflammatory drugs such as acetylsalicylic
acid (aspirin), indomethacin, phenylbutazone, and sulindac
partially protected the mice against the lethal effect of
endotoxin without affecting the ability of mice to produce TNF.
Mannoheptulose, through inhibition of insulin secretion
could reverse the hypoglybaemic effect of endo tox i_n during the
course of TNF production. Administration of mannooheptu1ose
partially protected mice infected with Listeria monocytoq ends
against the lethal effect of subsequent endotoxin challenge. The
ability of such treated mice to produce TNF was however
unaffected.
The synergistic actions of anti--inflammatory drugs and
mannoheptulose in the protection of mice infected with Listeria
monocytogenes against the lethal effect of endotoxin were
2observed. The protections in the combined treatments were better
than that of single drug treatments but the protections were not
complete. TNF activities in the sera of these mice were not
changed.
Some strains of LPS (E. coil 0127:B8, E. coli 0128:B12,
and Salmonella typhimurium), associated with different degree of
toxicity in the Listeria monocytogenes or C. Parvum infected
mice, had equable ability to induce TNF release into the sera of
such infected mice. Similar TNF titres were observed in sera of
mice treated with LPS (E. cola 0127:B8) extracted with phenol,
TCA, and butanol. Among these extraction methods, LPS prepared
by butanol had the least toxicity.
LPS consists of lipid A and carbohydrate. Lipid A or its
derivative- monophosphoryl lipid A retained the ability of LPS
to induce TNF release into the sera of mice. However, these
preparations were less effective In producing TNF than using
native LPS. Carbohydrate part lost this TNF-producing ability.
Monophosphoryl lipid A and carbohydrate component were non-toxic.
The rates of mortality of bacteria-primed mice challenged with
lipid A or native LPS were high.
The growth of Ehrlich ascites tumour (EAT) was inhibited
by tumour necrosis serum (TNS) or recombinant human tumour
5 necrosis factor (rTNF). Both TNS and rTNF (1.0 x 105-u/ml,
incubated for 30 hours) inhibited the glucose transport In EAT
cells. Rate of glucose uptake and the number of glucose carriers
were significantly decreased after these treatments. EAT treated
with rTNF also showed significant decreases in the rate of uptake
and incorporation of leucine. However, the rate of uptake and
3Incorporation of thymidirie, and uridlne were not. affected. The
uptake of calcium increased in such rTNF treated EAT while there
was no significant change In that of methlonire.
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1CHAPTER ONE
An overview of Tumour Necrosis Factor
A. Discovery of tumour necrosis factor (TNF):
The anti-tumour effects of bacterial cells and their
products have been known for over 100 years by Coley's
observation that spontaneous regression of certain human tumours
during bacterial infection in 1891 (reviews see, Ruff et al
1981a; Shier 1985). He then developed a bacteria-free filtrate
from two types of bacteria, Streptococcus Pyogenes and Serratia
Marcescens (Shier 1985). This filtrate is now known as "Coley's
toxin". Later, lipopolysaccharide (LPS), now recognised to be
endotoxin, was isolated from "Coley's toxin" by Shear (1944) and
the anti-tumour effects of "Coley's toxin" are attributed to
lipopolysaccharide. However, it was proved too toxic for use in
humans, and interest in "Coley's toxin" declined until it was
shown that endotoxin induced the release of tumour necrosis
factor (TNF) into the serum of mice infected with bacillus
Camette-Guerin (BCG) (Carswell et al 1975). TNF is therefore
defined as a substance that is found in the serum of animals
sensitized to BCG (or certain other immunopotentiators) and
challenged later with endotoxin and that causes the necrosis of
some tumours when passively transferred to tumour-bearing animals
(Ruff et al 1981a). Recently, it has been known that TNF and
lymphotoxin have similar and/or identical biologic activities in
several systems. Classical macrophage-derived TNF Is therefore
designated TNF-alpha while classical lymphocyte-derived
lvmnhnnxin as TNF-beta (Nedwin et al 1985; Kramer et al 1986).
2e. Production of tumour necrosis factor:
i) In vivo production of TNF:
According to Carswell et al (1975) and Green et al
(1977), there are two critical steps in the production of TNF in
animals. The first step involves priming animals with agents
such as bacillus Camette-Guerin (BCG). The function of these
agents is to activate reticuloendothelial system. Later, it is
known that many immunopotentlators can be used in the place of
BCG as the priming agent in the production of TNF. They include
Plasmodia (Clark et al 1981), Corynebacterium Parvum (Green et al
1977), Mycobacterium lepraemurium (Ha et al 1983), Listeria-
monocytogenes (Ha et al 1985a), Proplonibacterium (Bloksma et al
1983 Haranaka et al 1984a), Zymosan (Haranaka et al 1984a),
OK432 (Streptococcus Pyogenes group A type 3, Yamamoto et al
1986) and sheep red blood cells (Satoh et al 1986a). Recently,
Nedwin et al (1985) have reported that human peripheral blood
mononuclear cells (PBMC) can be induced by recombinant
interleukin-2 and mitogens to secrete TNF and lymphotoxin. The
second step involved in the production of TNF is to elicit the
bacteria-primed animals by small amount of endotoxin (carswell et
al 1975). Lipopolysaccharide (LPS) from E. Coll Is the commonest
choice although LPS from Streptococcus Pyogenes and Serratia
Marcescens may also be effective (Ruff et al 1981a). The
mechanism by which LPS exerts its ability to Induce TNF release
is not clear. It has been reported that lysosomal enzymes of
macrophage increase in proportion to TNF production even In
different strains of mice (Satomi et al 1981; Sakurai et al
1985). Furthermore, adrenaline has permissive action In
3eliciting TNF by LPS, suggesting that TNF release may be mediated
by the alpha-adrenergic receptor (Bloksma et al 1982). Recently,
it has been reported that it is required for the continual
presence of LPS in the experimental animals for the production of
TNF (Gifford et al 1986).
ii) Factors affecting in vivo TNF production:
The time interval between the injection of priming agent
and administration of LPS affects TNF activity produced in the
animals. The time interval varies with the strains of animals
and Lhe nature of priming agents used. For example, in the case
of Listeria as priming agent, it was found that TNF activity
could be obtained by eliciting with LPS from E. coil as early as
2 days post-infection and reached a maximum on day 4. TNF
activity was not detectable on day 11, even though at that time
the spleen and liver of animal were still grossly enlarged as
compared to normal control (Ha et al 1985a). For the case of
using LPS from E. coil as eliciting agent, TNF appeared In serum
of infected mice no sooner than 30 rain after LPS treatment and
reached a maximum after 2 hours. It was not found 6 hours
afterwards (Ruff et al 1981a Ha et al 1985a).
TNF activity also depends on the dose of priming agent
and eliciting agent. The larger the dose of these agents, the
higher is the TNF titre. However, the highest TNF titre cannot
be obtained by injecting relative higher dose of these agents
because all animals die out before blood collection for TNF. The
4
optimal dose of using Listeria appears to be 2x10 cells (Ha et
al 1985a), that of C. Parvum is 0.875mg (Green et al 1977) while
7
that of BCG Is 2x10 cells (Carswell et al 1975) per mouse. For
4eliciting agent, the optimal dose of LPS from E. cola is 25
microgram per mouse (Carswell et al 1975; Ha et al 1985a).
strains of animals also affect TNF production. It has
been reported that TNF can be produced in endotoxin-sensitive
strains of mice such as C3H/HeN, CD-1 (Swiss), ICR, DBA/2,
C57B1/8J, DDy, and AKR/J, but not in endotoxin-insensitive mice
such as nu/nu (Swiss), C3H/HeJ, and A/J (Green et al 1977; Mannel
et al 1979; Haranaka et al 1984b). Rabbits can also be used in
the production of TNF (Matthews 1978a).
iii) In vitro production of TNF:
It is known that alveolar, peritoneal macrophages, blood
monocytes, spleen macrophages or marrow cells from mice or
rabbits infected with Mycobacterium bovis or BCG release TNF into
the culture medium after stimulation with nanogram quantities of
bacterial LPS (Mannel et al 1980; Matthews 1981a; Satomi et al
1981).
C. Assay for tumour necrosis factor:
TNF activity can be determined by in vivo or in vitro
method, both in terms of its ability to induce cytotoxic/
cytostatic effects on tumour cells.
I) In vivo assay:
The original assay for TNF used by Carswell et al (1975)
is a visual observation of necrosis in subcutaneous transplants
of BALB/C sarcoma, Meth A. In negative response the tumour cells
remain intact, while in the maximum response the major part of
the tumour mass is destroyed, leaving only a pheripheral rim of
apparently viable tumour tissue. For better quantification, TNF
5activity can be determined by measuring tumour size (Bloksma et
al 1982 Haranaka et al 1984c). In our laboratory, Ehrlich
ascites tumour (EAT) cells is used as an assay model. Groups of
6
at least 6 mice are injected intraperitoneally with 2.5x10 or
7
10 EAT cells on day 0. One-tenth ml TNF-containing preparation
is injected intravenously on day 1 to day 6 post-implantation of
tumour cells. In control group, only buffer is injected. The
mice are killed by cervical dislocation on day 7. EAT cells are
collected by exhaustive drainage from peritoneal cavities and
tumour size is determined by viable cell counting with
haematocytometer (Fung et al 1985).
ii) In vitro assay:
The original in vitro assay described by Carswell et al
(1975) is to measure the viability of L-929 cells after TNF
treatment by trypan blue exclusion test. This method is
slightly modified in our laboratory (Ha et al 1985a). Briefly,
5
6.6x10 tumour cells (e.g. EAT; L-929) in 0.5m1 complete RPMI
1640 medium are added to each well of a 24-well Falco plastic
tissue culture plate. 0.5m1 of complete medium with different
0
dilutions of TNF are added. The plates are incubated at 37 C
for 1.8 hours. For suspension cultures (e.g. EAT), the viable
cell count is determined after addition 0.5ml 0.3% trypan blue to
each well. For adherent cells (e.g. L-929), the culture medium
is removed, 0.2m1 0.1% trypsin is then added and the mixture
0
incubated at 37 C for 5 to 10 min. After trypsinization, 0.8m1
0.1% trypan blue solution is added and the viable cell count
determined by haematocytometer. The viable cell number can also
be determined by photometric measurement after crystal violet or
6neutral red staining (Flick et al 1984). Alternatively, TNF
activity can be detected by measuring the radioactivity released
from tritium-thymidine pre-incorporated tumour cells (Mannel et
al 1980a). Tumour cells are prelabelled with tritium-thymidine
for 48 to 72 hours prior to distribution to microtiter plates.
Labelled tumour cells are incubated with TNF or control sample at
°
37 C and cytolytic effect is determined by counting the amount
of radioactivity released into culture medium. TNF activity can
be detected as early as 12 hours after TNF addition. To improve
the sensitivity, addition of actinomycin D at 1 ug/ml or
cycloheximide at 5 ug/ml to the TNF assay system enhances the
rate of cell killing 10-fold compared to the untreated control
(Ruff et al 1981a). It has also been reported that time of
incubation and cell seeding density affect TNF titre (Flick et al
1984).
D. Production site of tumour necrosis factor:
It has been speculated that TNF is a product released
from the activated macrophage. The reasons for this speculation
are as follows : a) the agents which prime for TNF production
cause marked macrophage hyperplasia (Old 1976; Green et al 1976),
b) selective lysis of splenic macrophage is seen shortly after
LPS injected into BCG-primed mice (Old 1976; Green et al 1976),
and c) serum containing TNF is rich in enzymes of lysosomal
origin (Old 1976 Green et al 1976; Sakurai et al 1981). This
speculation was supported by Satomi et al (1981) who, with the
aid of macrophage specific toxic chemicals such as carrageenan,
located the production site of TNF- activated macrophage.
7Moreover, the findings that in vitro production of TNF can be
obtained by incubating LPS with macrophage-enriched peritoneal
exudate cells, macrophage like tumour (PU5-1.8), blood monocytes
or spleen macrophages in the culture medium also prove that
macrophage is the main site of TNF production (Matthews 1978a
Mannel et al 1980b; Matthews 1981). Therefore, TNF is believed
to be a product of activated macrophage (Old 1976; Green et al
1976; Matthews 1978,1981; Satomi et al 1981). However, this
concept is challenged by Green et al (1982) for the following
reasons: 1) TNF production is not altered in C. Parvum-endotoxin-
treated mice by treatment with silica, a substance that is
specifically toxic for macrophages, and 2) exposure of mice to
650 rad whole-body radiation, which is not markedly damaging the
macrophage elements in the reticuloendothelial system, completely
abrogated the ability of mice to produce TNF after C. Parvum-
endotoxin treatment. The production site(s) of TNF other than
macrophage in animals remains to be elucidated.
E. Tumour necrosis factor susceptible cell lines:
TNF causes necrosis of certain transplanted tumours
without any cytotoxic effect on normal tissues in vivo and
regresses various kinds of tumour cells but not normal cells in
vitro (Carswell et al 1975; Nelson et al 1975; Matthews et al
1978b Matthews 1981b; Ruff et al 1981b). It is also shown that
TNF exerts its anti-tumour effects across the barrier of animal
species (Old 1985). The cytotoxic activity or cytostatic effect
of different sources TNF on various kinds of tumour cells is
summarized in table 1.1.
8Table 1.1 Effect of TMF on different cell lines:


























































9Table 1.1 Effect of TNF on different cell lines:













































Enhan. = EnhancementCytot. = CytotoxicCytos. = Cytostatic
Mu = MurineHu = HumanResis. = Resistant
r = recombinant
Table 1.1 Effect of TNF on different call lines:





















































































a: Ha et al (1985)
Green et al (1982)
Helson et al (1979)
b: Pennica et al (1985) c: Williamson et al (1983)
d: Wang et al (1985)
Sugarman et al (1985)
Hahn et al (1986)
Sohmura et al (1986)
e: Matthews et al (1978)
Ruff et al (1981b)
Haranaka et al (1985)
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F. Purification and cloning of tumour necrosis factor
Murine TNF induced by BCG or C. Parvum and LPS was
partially purified by Green et al (1976, 1979a, 1982); Kull et al
(1981a,1984) Mannel et al (1980c) using a series of steps
including ammonium sulfate fractionation, G-100 and G-200 gel
filtration, and preparative electrophoresis. Later, rabbit TNF
was purified to 1000 fold by affinity chromatography in addition
to conventional methods (Ruff et al 1980 Haranaka et al 1985).
Recently, large amount of TNF is produced from macrophage-tumour
cell lines (old 1985) and is purified by using high performance
liquid chromatography such as Mono Q (high-performance anion
exchange) column (Zacharchuk et al 1983 Beutler et al 195b).
Since TNF is induced by technique that causes general
reticuloendothelial hypertrophy, interferon is also induced into
the TNF-serum during TNF production. However, TNF activity cart
be separated from interferon in two ways: 1) Interferon is known
°
to be readily inactivated by heating to 56 C for 30 min (Kato et
al 1979 Bloksma et al 1982), while TNF is known to be stable at
this temperature (Table 1.2). Hence, it is necessary to heat
°
TNF-containing serum at 56°C for 30 min before measuring the TNF
activity. 2) TNF activity can be separated from interferon in
TNF-serum by passage through a Cibacron blue-agarose column or by
sequential salt precipitation, ion-exchange chromatography and
gel filtration (Matthews 1979).
Recently, complementary DNA (cDNA) encoding human TNF has
been cloned from induced HL-60 messenger RNA and directly
expressed in COS-7 cells or Escherichia cola for human TNF
(Shirai et al 1985; Wang et al 1985 Pennica et al 1984). The
12
gene product, recombinant human TNF, is a protein of 157 amino
acids probably with a single Intramolecular disulphide bond
between position 69 and 101. This mature human TNF is initially
synthesized as part of a 233 amino acids precursor. A murine
tumour necrosis factor (MuTNF) has also been obtained by the
expression of cDNA from murine macrophage-like cell line PU5-1.8
mRNA in Escherichia cola (Pennica et al 1985). This cDNA encodes
a mature MuTNF with 156 amino acids, leaving a long leader of 79
amino acids. Unlike human TNF, there is one potential N-
glycosylation site, located at asparagine-7 In MuTNF. This is
consistent with the report by Green et al (1976; 1982) that
murine TNF is a cellular glycoprotein. Whether the protein
component, i.e. recombinant murine TNF, attributes to all in vivo
or in vitro cytotoxic/ cytostatic effects on tumour cells by
native murine TNF remains further study. Furthermore, the
function of carbohydrate component in native murine TNF Is also
remains to be elucidated.
G. Physiochemical properties of tumour necrosis factor:
i) Physiochemical properties:
Several sources of native TNF have now been well
characterized. The physiochemical properties of mouse TNF,
rabbit TNF, and human TNF are summarized in Table 1.2. Mouse TNF
has low (50K to 60K)(Kull et al 1981a; Green et al 1976;1982
Haranaka et al 1986) and high (100K to 225K)(Green et al 1976;
Wang et al 1985) molecular weight forms. The high molecular
weight form may be due to aggregation in serum (Mannel et al
1980c). It should be noted that there appears species variation
Table 1.2 Physiochemical properties of TNP:
Native M u T N 1 r-Mu TNL- Native 11 u TNI.,,C r-Ilu TNL Native K abb it 'I' IJ!•'
Molecular Weight 50K- 6OK,
100K- 225K
17. 26K 4 0 K 17 K 3 0 K- 5 5 K
PI 4.8 N. L). 6.7 N.D. 4. 0
PH range 6-11 N.D. Acid lablite N.l). 5.5- 11
Nature Glycoprotein Protein Probably protein Protein Probably protein
Serum fraction Alpha-globulin N.D. Alpha-globulin N.D. Alpha-globulin
Heat stability 56°C- 60 min N.D. N.D. N.D. 56°C- 60 min









a: Mannel et al (1980c)
Kull et al (1984)
Green et al (1976)
Green et al (1982)
Haranaka et al (1986)
b: Pennica et al (1985) c: Rubin et al (1985a)
Kelker et al (1985)
d: Wang et al (1985)
Pennica et al (1984) e: Haranaka et al (1985)
N.D.- Not done Mu= Murine r= recombinant Hu= Unman
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in the extent of TNF glycosylation. It has been reported that
mouse TNF is a glycoprotein (Green et al 1976,1982; Nelson et al
1979) while rabbit TNF and human TNF are probably proteins since
they fail to bind to the Con-A-Sepharose or to several other
agglutinin-Sepharose columns specific for carbohydrate moieties
common in glycoproteins (Kelker et al 1985; Haranaka et al 1985).
The properties of recombinant mouse TNF and recombinant human TNF
remain further characterization.
ii) Metabolic fate of tumour necrosis factor in vivo:
TNF has some unique characteristics such as lack of
species specificity and the ability to discriminate between
normal and certain tumour cells in vitro. The in vitro cell
killing effects of TNF are believed to be due to the same factor
as that which causes hemorrhagic necrosis in vivo (Carswell et al
1975; Helson et al 1975; Matthews et al 1978; Matthews 1981b;
Ruff et al 1981a,b). However, the in vivo administration of TNF
provides a new approach to the immunotherapeutic treatment of
tumour while the in vitro study provides a model for the
examination of the action mechanism of TNF on tumours. It has
been reported that TNF has a clearance of 0.013m1/min/g and is
cleared from the plasma with a half-life of 6 to 10 min (Beutler
et al 1985a Flick et al 1986). Most of the TNF are taken up by
liver, kidneys, skin and gastrointestinal tract and degraded
rapidly in peripheral tissues of the body without formation of
detectable intermediate products (Beutler et al 11985a). Thus
two methods can conceivably be used to produce longer exposure
periods for successful eradication of tumours. One is to give art
extremely high single dose of TNF while the other Is to
15
administer frequent lower dose of TNF or maintain consistent
infusions over an extended period (Flick et al 1986).
iii) Comparison of human TNF and Human lymphotoxin:
Macrophage-derived human TNF, both natural and
recombinant, are non-glycosylated protein. Recombinant human TNF
has molecular weight of approximately 17K and consists of 157
amino acids, two of which are cysteines joined by a disulfide
bond (Pennica et al 1984 Wang et al 1985). Lymphocyte-derived
human recombinant lymphotoxin is also non-glycosylated and has
molecular weight of approximately 18.6K and consists of 171 amino
acids and only one cysteine residue while natural lymphotoxin is
glycosylated and has molecular weight of approximately 25K
(Nedwin et al 1985 Gray et al 1984). The difference In
molecular weight between natural and recombinant lymphotoxin is
due to glycosylation of natural molecule. it has known that TNF
has about 30% homology in its amino acid sequence with
lymphotoxin and that they appear to be nearly identical with
respect to their biologic activity (Nedwin et al 1985 Gray et al
1984). However, they are antigenically distinct molecules, le.,
the lymphotoxin antibodies do not neutralize TNF activity and the
TNF antibodies do not neutralize the activity of lymphotoxin
(Nedwin et al 1985). Recently, a new developed serum-free
bioassay is applied to differentiate them (Kramer et al 1986).
H. Mechanism of action of tumour necrosis factor:
In spite of the fact that the existence of TNF was
reported 12 years ago, progress in the study of its mechanism of
action was hampered by the lack of pure material. Recently,
16
availability of highly purified human TNF produced in Escherichia
cola by recombinant DNA technology (Wang et al 1985; Pennica et
al 1984) has made it possible to study the initial stages of TNF
action. It has been reported that TNF binds specifically to
human or mouse cell lines sensitive to the cytotoxic effect of
TNF, but not to some cells made resistant to TNF (Rubin et al
1985b Umeda et al 1983). TNF-sensitive cells have cell surface
receptors with a high affinity for TNF. However, it was known
that TNF also bond to some TNF-resistant cells such as FS-4
(Tsujimoto et al 1985 Kull et al 1985 Scheurich et al 1986)
with high affinity as sensitive cells. Thus, the presence of the
binding site appears to be necessary but not sufficient to
explain the sensitivity of cells to the cytotoxic action of TNF.
This was supported by the fact that interferon-gama increased the
cytotoxic effect of TNF (Williamson et al 1983) possibly by
enhancement expression of cellular receptors for TNF (Tsujimoto
et al 1986 Ruggiero et al 1986).
Although it is not clear whether receptor-mediated
endocytosis and intracellular degradation of TNF are required for
biological activity of TNF these steps occur after TNF binding
to cell surface receptors (Tsujimoto et al 1985; Kull et al
1981b). Internalization and subsequent intracellular degradation
was. found in both TNF sensitive and resistant cell lines
Tsujimoto et al 1985), an explanation for the vastly different
sensitivity may be due to the cell cycle-specificity
(Darzynkiewicz et al 1984) or the activation of TNF (as zymogen)
by lysosomal enzymes (Ruff et al 1981a) in different cell lines.
In a simple sense, TNF must be inhibitory to all anabolic
17
pathways. However, a very interesting paradoxic._t1 result
reported by Ostrove et al (1979) that there was an increase in
uridine incorporation in.crude TNF-treated L-929 cells. They
further reported the synergistic effect of actinornycin D on TNF
induced cell killing, which was interpreted to imply a repair
mechanism. New transcription may be required to repair or
replace a TNF-damaged cellular component. But the burst of
synthesis occurred rather late in the course of TNF action (24
hr) and cells had already died by 4 to 6 hr made this model
become unfavorable. A model for cell killing whose general
features incorporate both the specificity and catalytic
properties of an enzymatic reaction is therefore proposed for TNF
action (Ruff et al 1981b). This model would help explain the
following results: a) one molecule of TNF can kill more than one
cell, b) L-929 cells are considerably more resistant to lysis at
25 C and show enhanced killing at 39 C as compared to 37 C
control but no killing effect at 4 C. (Matthews et al 1978b Ruff
et al 1981c). In fact, the mechanism of action of TNF is
unknown. Since cell death must necessarily be the last of
perhaps many intervening events and must also be the converging
point for any substance that kills a cell, further work to
elucidate the mechanism by which TNF exerts its cytotoxic or
cytostatic effect must focus on the earliest alternations within
the cell.
I. Biological effects induced by tumour necrosis factor:
In addition to the anti-tumour effect, TNF influences
immunological functions such as the replacement helper T cells in
18
the humoral immune response and induction phenotypic lid
functional differentiation of B lymphocytes (Hoffmann et al
1976). Moreover, it was known that TNF can protect animal
against micro-organisms infection (Parant 1980), induce a
serologically distinct population of natural killer cells (Churl
et al 1979), and enhance the natural cytotoxicity of lymphoid
cells in vitro (Pasanen 1979). Thus, TNF may exert its cytotoxic
or cytostatic effects on tumour cells in vivo directly or
mediated by modification of immune system. Malarial parasites
killing ability is another side beneficial effects induced by TNF
(Taverne et al 1981 Haidaris et al 1983). Later, it was found
that TNF had no direct effect on the parasites but enhanced
eosinophil toxicity to the parasites in a dose-dependent fashion
(Silberstein et al 1986). However, TNF, especially for
recombinant TNF, also induced some undesirable biological effects
such as depression of liver drug metabolizing enzymes (Ghezzi et
al 1986),action as one of the principal mediators of the lethal
effect of endotoxin (Beutler et al 1985c Tracey et al 1986),
enhancement of the adherence of human peripheral blood
neutrophils to human umbilical vein endothelial (HUVE) cell
monolayers (Gamble et al 1985). The adherence of blood cells to
endothelium is a central reaction in the development of
inflammatory reactions (Gamble et al 1985). Inhibition of bone
formation in vitro by human recombinant tumour necrosis factor
has been reported recently by Bertolini et al (1986). The above
biological effects seem to be identical to those induced by
cachectin. Cachectin, a protein secreted by macrophages in
response to endotoxin, is assayed by its ability to suppress the
19
activity of lipoprotein lipase in vivo and in vitro (Beutler et
al 1985b;c;d). This protein has an isoelectric point of 4.7 and
a subunit molecular weight of 17000 (Beutler et al 1985d; 1986).
The predominant physiological function of cachectin remains to be
determined. Presumably, the ability of cachectin to activate
neutrophils and eosinophils, and to mobilize energy stores,
confers an advantage on the host (Beutler et al 1986). However,
when cachectin is released in large quantities, the resulting
metabolic derangement can be catastrophic, hypertriglyceridemia,
and wasting syndrome (Old 1985), leading ultimately to death of
the individual (Beutler et al 1986). Most recently, recombinant
human TNF has been suggested to be identical to cachectin
(Beutler et al 1986b;c; Tracey et al 1986).
J. Clinical application of tumour necrosis factor:
The lack of species specificity and selectively attacking
/ destroying cancer cells trigger the interest in clinical trials
with TNF in 1985 on cancer patients at Memorial Sloan Kettering
Cancer Center in New York City and in other major centers. Later
this year, clinical trials with TNF and interferon-gama in
combination will also begin on cancer patients (Palladino et al
1986). The availability of large amounts of recombinant TNF
should facilitate its potential application in clinical medicine
against tumours that are hard to combat with conventional




Tumour necrosis factor (TNF) was first discovered by
Carswell oot al (1975) in the serum of endotoxin - treated mice
which had been previously infected with Mycobacterium bovis
strain BCG. TNF caused a hemorrhagic necrosis of various tumours
in mice with no apparent effects on the host. Tumour cells in
culture were also inhibited or killed by TNF whereas normal cells
were not affected (Old 1985). Later, it was known that murine
TNF had an inhibitory effect on human melanoma cells growing in
culture showing that TNF was not species specific (Old 1985).
Thus, there has been a growing interest in investigating the
methods for producing large amount of TNF and the mechanism by
which TNF exerted its cytotoxic or cytostatic effect on tumour
cell.
Endotoxin (lipopolysaccharide) is highly toxic for
animals especially when the animals are primed with micro-
organisms. Toxicity is possibly the consequence of the variety
of biological effects. Animals may suffer from different
pathologic changes and even death (Berry 1977). Induction of TNF
production in situ as a therapeutic measure is therefore severely
curtailed because of the often lethal effect of endotoxin. It is
of clinical interest to alleviate this side effect by utilizing
suitable priming agent and suitable LPS component / or
components which only stimulate TNF secretion without causing
undesirable biologic effects. For priming agents,
Corynebacterium Parvum (C. Parvum) is the best candidate because
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it is safe even to human and has been accepted as an anti-tumour
drug clinically. However, the whole organism usually causes some
contrary diverse effects. It is believed that C. Parvum contains
multi-components which activate independently the sub-population,
of macrophages to produce TNF. In order to eliminate the side
effect, it is reasonable to study which component of C. Parvum is
effective in producing TNF. It has reported that C. Parvum-
pyridine extract can activate macrophage and C. Parvum- pyridine
extract residue cannot activate macrophage (Mukai et al 1986).
These preparations have been tested for their capacities to
produce TNF (Chapter 4).
The use of endotoxin, i.e. lipopolysaccharide (LPS), as
an eliciting agent in the course of production of TNF is the
main step which produces toxic effects (Berry 1977; old 1985),
owing to the fact that there is no other available substance that
can be used in place of LPS during TNF production, research is
concentrated on the studying of the relationship between the
structure of LPS and its corresponding biological effects. Three
common methods can be applied to minimize, or eliminate LPS side
effects. They are : a) radio-detoxification of LPS by
60
irradiation at 200 KGY using Co source, b) drugs counteract the
undesirable effects induced by LPS, and c) chemical modification
of LPS. In this thesis, the latter two methods are applied.
LPS causes severe hypoglycaemia presumably via
stimulation of insulin secretion (Witek-Janusek et al 1983) and
enhancement of production and release of prostaglandins (Berry
1977). These biochemical changes disturb the homeostasis of the
body severely that results in the death of animals. The non-
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steroidal anti-inflammatory drugs and insulin inhibitors are
therefore used to study whether they can protect animals against
lethal shock by restoring the homeostasis as quickly as possible
without affecting the ability of animals to produce TNF (Chapter
567). In addition to this, chemical modification of LPS might
eliminate toxicity while maintaining some of the beneficial
effects. It is believed that many biological effects induced by
LPS are attributed to the toxic center, lipid A (Ha et al 1985a).
More attention is therefore paid to this lipid moiety in order to
find out non-toxic chemical structures that still retain the
ability to induce TNF release (Chapter 8).
Despite intensive research has been carried out during
the last decade, the mechanism of action of TNF is still unclear.
It has been reported by Fung et al (1985) that tumour necrosis
serum (TNS) can inhibit the glucose transport in Ehrlich ascites
tumour (EAT) cells both in vivo and in vitro. It is quite clear
that this factor-containing serum must exert a direct action on
the tumour cells in vitro. However, TNS Is a crude serum
containing not only TNF, but also a variety of lysosomal and
cytoplasmic enzymes plus cytoplasmic contents of mononuclear
phagocytes which might cause artifacts. In this respect,
recombinant human tumour necrosis factor (rTNF) (from Genentech,
Inc.) is therefore used to confirm the above mentioned findings.
Since rTNF has 30% homology in its amino acid sequence with
lymphotoxin (Nedwin et al 1985 Gay et al 1984) and It has been
reported by Okamoto et al (1978) that the primary action of
lymphotoxin involves creation of Ionic imbalances within the
target L cells, it is of interest to study whether rTNF can also
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All materials and general methods are described in this
chapter. specific methods or procedures will be-described in the
"Experimental" section of the related chapter.
A. Materials:
All chemicals were of the "Analytical Reagent (AR)" grade
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Ajax : Ajax Chemicals, Australia.
Amersham : Amersham International Ltd., England.
BDH : British Drug House Chemical Ltd., England.
C.M.L. : Clinical Microbiology Lab., Queen Mary Hospital,
University of Hong Kong.
Difco : Difco Laboratories, U.S.A.
Fisher : Fisher Scientfic Company, U.S.A.
Genentech : Genentech, Inc., South San Francisco, U.S.A.
Genzyme : Koch- Light Ltd., England.
Gibco : Grand Island Biological Co., Scotland.
M & B : May & Barker Ltd., England.
Mallinckrodt : Mallinckrodt, Inc., U.S.A.
Merck : E. Merck, F.R.G.
NEN : New England Nuclear, U.S.A.
Peking : Peking Chemical Works, Peking, China.
Ribi : Ribi Immunochem Research, Inc., Hamilton.
Roche : F. Hoffmann- La Roche Co., Ltd. Co., Switzerland.
Sigma : Sigma Chemical Co., U.S.A.




ICR strain of mice (30-35 g body weight) were used. They
were kept in air conditioned rooms and fed standard laboratory
'chow' and tap water ad libitum.
ii) Cell culture methods:
All manipulations for cell culture were performed under a
laminar flow hood (Baker) with sterilized instruments and
glasswares.
Preparation of culture medium:
The growth medium for cell culture in our experiments was
RPMI 1640. The medium was prepared with double-distilled water
and supplemented with 25 mM HEPES and 25 mM NaHCO according to
3
the manufacturer's specifications. The medium was sterilized by
°
passage through a 0.45 um millipore filter and stored at 4 C.
Sterility was tested by incubating the filtered medium in culture
°
tubes at 37 C for 3 days. When use, the medium was further
supplemented with 50 units/ml penicillin, 100ug/ml streptomycin
and 10% (v/v) fetal calf serum or heat-inactivated fetal calf
°
serum which had been incubated at 56 C for 30 min. The medium
was defined as complete RPMI 1640 medium. Complete RPMI 1640
medium with fetal calf serum was used for maintaining cell line
while that with heat-inactivated fetal calf serum was for in
vitro assay.
Ehrlich ascites tumour (EAT) cell culture:
The culture of EAT cells were established by collection
of cells asceptically from tumour bearing mice, and immediately
washed twice with sterile PBS. The washed cells were then
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resuspended in complete RPMI 1640 medium. Cells were seeded into
2 5
25 cm culture flasks at 2x10 cells/ ml.
°
After incubation at 37 C for 24 hours, the suspended
cells were collected and seeded into flasks. The same procedure
was repeated twice and the cells were then passaged routinely.
EAT cells in culture was passaged every 3-4 days by 10 fold
dilution with fresh complete RPMI 1640 medium. Cells between 16-
50th passages were used for experiments.
For cell storage, cells which were in the logarithmic
phase of growth and Just approaching confluency were collected
6 7
and resuspended at approximately 5x10 -2x10 cells/ml in culture
medium containing 25% calf serum and 15% preservative such as
dimethyl sulphox ide (DMSO). Cell suspensions were dispensed
into 1.8 ml ampoules and sealed. The ampoules were then cooled
° °
to -20 C for 1 to 2 hours and transferred to -70 C refrigerator
for overnight. The cooled ampoules were rapidly transferred to a
°
liquid nitrogen refrigerator at -196 C. When used, ampoules
were removed from the liquid nitrogen refrigerator and
°
immediately plunged into water bath at 37 C followed by slight
agitation to assist the thawing of the contents. As soon as the
contents had thawed (within 60 seconds) the ampoules were removed
from the water bath, dried and swabbed with 70% ethanol. The
ampoules were opened and the contents were transferred to
sterilized culture tube containing complete RPMI 1640 medium.
Cells were washed twice with complete RPMI 1640 medium. The
washed cells were then resuspended In the fresh complete RPMI
2 5
1640 medium and seeded into 25 cm culture flasks at 2x10
cells/ ml.
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To determine cell count, cell suspension of appropriate
dilution was introduced onto the ruled counting area of a
hemocytometer (American opticals) under the coverslip. The
number of cells was counted under a phase contrast microscope
(Nikon) using the tally counter to record numbers. Cell
concentration in original suspension was calculated according to
4
the following formula: TC= N x D x 10 cells/ ml where TC was
the total cell number in cell suspension, N was the number of
cells visible over the center area in hemocytometer while D was
the dilution factor.
iii) Bacteria:
Listeria monocytogenes was obtained from Clinical
Microbiology Laboratory, Queen Mary Hospital, University of Hong
Kong and passaged in mice (Gardner 1980). Bacteria used for
infection was obtained from overnight culture of Listeria in
tryptic soy broth.
iv) Production of TNF in animals:
TNF containing serum was obtained from mice injected
4
intravenously with 10 Listeria monocytogenes in 0.2 ml saline
or intraperitoneally with 0.875mg Corynebacterium Parvum in 0.2
ml saline and challenged intravenously with 25ug LPS from E. coil
0127:B8 5 days after Listeria infection or 10 days after C.
0
Parvum injected. The serum was filter-sterilized, heated at 56
0
C for 30-min and stored at -20 C until use.
v) Mortality determination:
Bacteria- primed mice were observed at different time
interval after LPS injection. The percentage of survival was
calculated by the following formula:
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Percentage of survival survived mice at different time
at different time
Total mice
vi) Determination of TNF titre:
5
6.6 x 105 viable cells in 0.5 ml complete RPMI 1640
medium were added to each well of a 24-well Falcon plastic tissue
culture plate (Becton, Dickinson &Co., Oxnard). 0.5 ml of
complete medium with different dilutions of sample was added.
Then four microliter of cycloheximide (250ug /ml) was added to
°
each well. The plates were incubated at 37 C for 18 hr. In
5
some experiments, 2 x 10 cells were added to each well and
cultured for 48 hr. For suspension cultures, the viable cell
count was determined after addition of 0.5 ml 0.3% trypan blue to
each well. For adherent cells, the culture medium was first
removed 0.2 ml 0.1% trypsin (Gibco) was then added and the
°
mixture incubated at 37 C for 10 min. After trypsinization, 0.8
ml 0.1% trypan blue solution (with 1% fetal calf serum) was added
and viable cell count determined.
The percentage target cell inhibition (T.I.) of cells at
each dilution of sample was calculated by the following formula
T.I.= (100(N-E)/Nl% where N = number of viable cells per culture
with control sample and E= number of viable cells per culture
with sample with TNF activity. T.I. 50 is defined as the
concentration of sample (v/v) in culture medium such that T.I. of
this culture is 50%. The TNF titre is defined as the reciprocal




Effect of pyridine extract of Corynebacterium Parvum
on the production of tumour necrosis factor in mice
INTRODUCTION
Corynebacterium Parvum (C. Parvum) is a very short, Gram-
positive rod showing some degree of bipolar staining, generally
more intense at one end than the other (Cummins et al 1974).
Recently, much evidence indicates that killed suspension of
Corynebacterium Parvum serves as an immunotherapeutic agent in
the treatment of human malignant disease (Scott 1974; Cantrell et
al 1979). The use of Corynebacterium Parvum for clinical trials-
in cancer patients has triggered an increasing interest in the
chemical nature of the molecular structures responsible for its
immunotherapeutic effect. Different extraction methods such as
phenol-water extraction or pyridine extraction were applied to
examine whether one component or a complex of different
components in C. Parvum corresponding to a certain specific
biological effect. It was found that C. Parvum organism
contained multiple determinants that independently activated
different macrophage subpopulation (Lichtenstein et al 1982). It
has been reported that C. Parvum- pyridine extract (CP-PE) and
C. Parvum- pyridine extract residue (CP-PER) possess a stronger
anti-tumour effect than C. Parvum- whole cell (CP-WC) (Mukai et
al 1986).
Tumour necrosis factor (TNF) was first discovered by
Carswell and her colleague in 1975 (Carswell et al 1975) in the
serum of mice infected with bacillus Camette- Guerin (BCG) and
challenged subsequently with endotoxin. Later, it was shown that
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Corynebacterium Parvum can substitute BCG as the priming agent in
the production of TNF (Green et al 1977). However, animals are
hypersensitive to the lethal effect of endotoxin (i.e.
lipopolysacchari.de, LPS) by pretreatment with immunomodulating
agents like bacillus Calmette- Guerin (BCG) or Corynebacterium
Parvum (C. Parvum) (Carswell et al 1975). It is therefore
reasonable to study whether pyridine extracted fraction of
Corynebacterium Parvum (CP-PE) or pyridine extracted residue of
Corynebacterium Parvum (CP-PER) which have been reported to
process higher anti-tumour activity than the whole cell (Mukai et
al 1986) can minimize the lethal effect of LPS during TNF




Male ICR strain of mice, about 35g body weight, were
used. Formalin - killed C. Parvum whole cell (strain CN 6134)
was obtained from Wellcome Research Laboratory. C. Parvum
(strain 4182)-whole cells, pyridine extract and pyridine extract
residue were products of Ribi Immunochem. Research, Inc. Lipo-
polysaccharide W (E. cola, serotype 0127:B8) (LPS) was purchased
from Sigma. Glutamic-oxalacetic transaminase (GOT) and glutamic-
pyruvic transaminase (GPT) were determined by GOT colorimetric
test kit and GPT colorimetric test kit from Roche respectively.
Groups of 8 mice were injected intraperitoneally with 0.2
ml saline containing 0.875 mg C. Parvum or C. Parvum fractions
and challenged Intravenously with 25 ug LPS in 0.2 ml saline 10
days afterwards. Mice were bled from their subclavian vessels 2
hr after LPS Injection. Sera were pooled. One part was used for
GPT / GOT determination while the other one was for TNF assay.
°
For TNF assay, sera were filter-sterilized, heated at 56 C for
°
30 min and stored frozen at -20 C until use. Normal serum was
obtained from mice without any treatment. TNF titre was
determined as described in Chapter Three "Materials and Methods".
Spleen and liver of each mouse were dissected and the
blood was blotted with filter paper. The body weight and weight
of -spleen and liver of each mouse were recorded. The liver /
body weight ratio or spleen/ body weight ratio were calculated
by dividing the liver weight or the spleen weight by the
corresponding body weight of each mouse.
For mortality determination, 14 mice were monitored post-
LPS treatment for 48 fours.
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RESULTS
The mortality of C. Parvum or C. Parvum fractions
injected mice was monitored for 48 hr after being challenged with
LPS. The results in Fig.4.1 showed that C. Parvum (Wellcome
strain CN 6134) rendered mice hypersensitive to the toxic effect
of LPS 50% such treated mice died about 1 hr after LPS injection
and the percentage survival maintained at 14% afterwards. Mice
treated with C. Parvum (strain 4182)-whole cell (CP-WC), C.
Parvum-pyridine extract (CP-PE) or C. Parvum-pyridine extract
residue (CP-PER) rendered the mice less sensitive to endotoxin
toxicity as compared with that of C. Parvum strain CN 6134. The
descending order of the percentage survival among these three
groups are C. Parvum-PE, C. Parvum-PER and C. Parvum-WC. C.
Parvum strain CN 6134 has been used as a priming agent in the
production of TNF (Green et al 1977) while there has been no
information concerning the use of C. Parvum strain 4182 in TNF
production. It is of interest to study whether these non-toxic
C. Parvum strain 4182 and fractions have an ability to act as a
priming agent in the production of TNF. TNF activity, GOT/ GPT,
liver size, and spleen size in such C. Parvum strain 4182 whole
cell or fractions- treated and LPS- challenged mice were
studied. The results were summarized in Table 4.1. Liver-to-
body weight ratio and spleen-to-body weight ratio in normal mice
were 0.051+ 0.010 and 0.0.045+ 0.0007 respectively. Mice
treated only with 25ug LPS showed no significant difference from
the normal mice in liver size or spleen size. The ability of C.
Parvum strain 6134 to induce hepatomegaly (liver/body
weight=0.095+ 0.014) and splenomegaly (spleen/body
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weight=0.0091± 0.0028) were marked while that induced by C.
Parvum strain 4182-whole cells and C. Parvum strain 4182-pyridine
extract residue were moderate and that induced by C. Parvum
strain 4182-pyridine extract were slight. It was also found that
C. Parvum or fractions which could exhibit higher degree in
liepatomegaly or splenomegaly in mice could also render the
animals more sensitive to endotoxin (LPS) destruction as
expressed by GOT index or GPT index. Single dose of 25ug LPS
treatment increased GPT index about 40% but no significant change
in GOT index was found as compared with normal. However, C.
Parvum strain 4182 whole cell or pyridine extract or pyridine
extract residue caused 2-3 folds increases in GOT index and 2-4
folds increases in GPT index as compared with normal. C. Parvum
strain CN 6134 caused even drastically increased changes, 4 folds
increases in GOT index and 7 fold increases in GPT index. TNF
activity was found in the serum of mice primed with C. Parvum or
C. Parvum fractions and challenged subsequently with LPS. There
was no TNF activity in the serum of normal mice or mice treated
with LPS only. C. Parvum strain CN 6134 was a good priming agent
in the production of TNF. By using such C. Parvum, TNF titre was
about 2500. C. Parvum strain 4182-whole cells, C. Parvum strain
4182-pyridine extract residue and C. Parvum strain 4182-pyridine
extract were weak priming agents for TNF production and TNF titre








TIME AFTER LPS INJECTION (hr)
Fig. 4.1 Effect of C. Parvum or fractions on the
sensitivity of mice to endotoxin shock. Groups of 14
mice were injected intraperitoneally with 0.875mg C.
Parvum or fractions in 0.2m1 saline and challenged
intravenously with 0.2m1 saline containing 25ug LPS 10
days afterwards. mice were monitored for 48 hr after
LPS injection. C. Parvum strain CN 6134 was indicated
by while C. Parvum strain 4182 was by
and represented C.
Parvum strain 4182-pyridine extract and C. Parvum-strain





Table 4.1 Effects of C. Parvum and C. Parvum fractions on spleen liver, GPT, GOT and THE activit
TNF titre GPT indexGOT indexSpleen / B. W.Liver / B. W.
7.29 1 0.414.30 1 0.3125000.0091 ± 0.00280.095 ± 0.014C.Parvum strain
CN6134
4.59 ± 0.52250 3.63 ± 0.220.0050 ± 0.00110.075 ± 0.006C. Parvum strain
4182(whole cell)
4.59 ± 0.3980 2.89 ± 0.5410.073 ± 0.009 0.0053 ± 0.0016Parvum strain
4182 (PER)
Parvum strain 0.063+ 0.003 0.0047+ 0.0001 60 2.00 ± 0.362.11 ± 0.25
4182 (PE)
Normal (no treated) 0.051 ± 0.010 0.0045 ± 0.0007 1.00 1.00
0.059 ± 0.003 10.0040 ± 0.0007 0.93 ± 0.06LPS (only) 1.41 ± 0.62
Groups of 8 mice were injected intraperitoneally with 0.2ml saline containing 0.875mg C,
Parvum or C, Parvum fractions and challenged intravenously with 25ug LPS in 0.2m1 saline 10
days afterwards.
Mice were bled from their subclavian vessels 2 hr after LPs injection. Pooled sera from
groups of 8 mice were used for GOT, GPT and TNF assay. Spleen and liver were dissected tc
determine their weight.
GOT index and GPT index were defined as the serum GOT and GPT values of treated mice divided
by the corresponding values of normal mice.
Data are expressed as mean + SEM of 8 mice per group.
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DISCUSSION
Tumour necrosis factor (TNF) was first discovered by
Carswell and her colleague in 1975 in the serum of mice infected
with bacillus Calmette- Guerin (BCG) and challenged subsequently
with LPS (Carswell et al 1975). Later, it was found that
Corynebacterium Parvum (C. Parvum) could substitute BCG as
priming agent in the production of TNF. However, Injection of C.
Parvum caused some diverse effects such as cytotoxicity mediated
by natural killer cells might be altered (Oehler et al 1978;
Flexman et al 1980). Based on the report that C. Parvum organism
contained multiple determinants that independently activated
different macrophage subpopulation (Lichtenstein et al 1982), we
study the ability of TNF production of preparations extracted by
pyridine of C. Parvum strain 4182. It has been reported
(Lichtenstein et al 1982) that the recovered material in C.
Parvum-pyridine extract (CP-PE) was 9% while in C. Parvum-
pyridine extract residue (CP-PER) was 91%. CP-PE had higher fatty
acid content but less protein content as compared with CP-PER.
Both CP-PE and CP-PER contained same amount of carbohydrate.
As shown in Fig. 4.1, mice injected with C. Parvum strain
4182-whole cells (CP-WC), C. Parvum strain 4182-pyridine extract
(CF-PE) or C. Parvum strain 4182-pyridine extract residue (CP-
PER) exhibited less sensitive to endotoxin shock as compared
with those injected C. Parvum strain CN 6134 which has been
reported to be a priming agent in the production of TNF (Green et
al 1977). it is therefore reasonable to evaluate the ability of
C. Parvum strain 4182 and their pyridine extraction products to
act as a priming agent during TNF production. CP-WC and CP-PER
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had moderate ability to induce hepatomegaly and splenomegaly
(Table 4.1). Hepatic cells in such treated mice were sensitive
to endotoxin destruction as indicated by 3-4 fold increases of
GOT Index and GPT Index. CP-PE was a weak immunostimulator in
this aspect, only about 2 fold increases of GOT index and GPT
Index were observed. To study their abilities to act as a
priming agent in the production of TNF, TNF activity in the serum
of mice primed intraperitoneally with C. Parvum or fractions and
subsequently challenged intravenously with LPS was determined.
It was found that CP-WC could produce TNF titre of 250 while only
80 and 60 were obtained in mice primed with CP-PER and CP-PE
respectively (Table 4.1). It is suggested that the components in
the whole cell of C. Parvum are essential to produce TNF. It was
also found that C. Parvum strain 4182 whole cell exhibited only
moderate abilities in TNF production as compared with C. Parvum
strain CN 6134 which produced high TNF titre. Only one tenth of
TNF activity was produced by strain 4182 as compared with that by
strain CN 6134 grade I, this result indicated that there existed
strain specificity in the Corynebacterium Parvum (C. Parvum) in
TNF production. This result is consistent with that reported by
Green et al (1979b) that different strain of C. Parvum had
different ability to induce TNF. Based on the evidence that C.
Parvum organism contained multiple determinants that
independently activated different macrophage subpopulation
(Lichtenstein et al 1982), C. Parvum strain 4182 may contain only
a little amount of an active component or a complex of different
components to activate certain macrophage subpopulation for TNF
production. It has been believed that TNF and other
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biomodulators are products released from activated macrophage
(Carswell et al 1975 Satomi et al 1981), CP-PE and CP-PER,
though producing less TNF-titre, possess a stronger anti-tumour
effect than CP-WC (Mukal et al 1986), indicating that they may
produce other modulators. It is interesting to study the use of
pyridine extraction method to extract active components in C.
Parvum strain CN 6134 for TNF production so as to minimize some




Effect of anti-inflammatory drugs on the production
of tumour necrosis factor and lipopolysaccharide
induced - mortality in mice
INTRODUCTION
Bacterial lipopolysacchar ides (LPS) (also termed as
endotoxins) have a wide range of pathophysiological effects. One
of these effects is the induction of the release of tumour
necrosis factor (TNF) into sera of animals injected with
Corynebacterium Parvum or Laster is monocytogenes (Carswell et al
1975; Ha et al 1985a). LPS Is also highly toxic for animals
primed with these micro-organisms, possibly as a consequence of
the increased production and release of prostaglandins as well as
that of a glucocorticoid antagonising factor and a variety of
vasoactive mediators (Berry 1977). The usefulness of LPS in the
production of TNF is therefore severely curtailed. However,
previous studies have shown that certain non-steroidal anti-
Inflammatory drugs such as acetylsalicylic acid, indomethacin,
sulindac and phenylbutazone can block certain stages in the
haemodynamic effects of LPS and protect the LPS-treated animals
(Erdos et al 1967; Goodrum et al 1978; Cook et al 1979).
Acetylsalicylic acid itself is an irreversible inhibitor, which
covalently acetylates lysine residue in the active site of cyclo-
oxygenase (Higgs et al 1983). This enzyme converts arachidonic
acid into prostaglandins such as thromboxane A 2 and it has been
Yeported that endotoxic shock mediated the elevation of
thromboxane A (Cook et al 1979). Phenylbutazone inhibited both
2
the classical and alternative complement pathway activities by
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preventing complement system from generating C5a (Manta et al
1983) and it, has been reported that histamine released from mast
cell by the action of activated complement system can stimulate
the production of prostaglandins (Roitt et al 1985).
Indomethacin and sulindac have both anti-complement activity
(Minta et al 1983) and inhibition of prostaglandins synthesis
(Higgs et al 1983). In view of the therapeutic potential of TNF,
it would be of interest to examine if these drugs could modulate
the production of TNF and the lethal shock reaction that is




Male ICR strain of mice, about 35g body weight, were used
in all experiments. Listeria monocytogenes was cultured in
tryptic soy broth as described previously (Ha et al 1985a).
Bacteria used for infection were obtained from overnight
cultures. Corynebacterium Parvum (strain CN 6134) was from
Wellcome Laboratories (Beckenham, Kent). Lipopolysaccharlde W.
(LPS, Escherichia coli, serotype 0127:B8) was purchased from
Sigma (St. Louis, Mo).
Acetylsalicylic acid was a product of Merck (Darmstadt).
Indomethacin and phenylbutazone were obtained from Sigma.
Sulindac was purchased from Merck (Rahway). Indomethacin (10mg/
ml) was dissolved in propan- 1,2- diol and phenylbutazone (6mg
/ ml) in 0.1 M Tris-HC1 buffer, pH 9.4. Acetylsalicylic acid and
sulindac were dissolved in water. The solutions were adjusted to
pH 7.0 with 0.5 M NaOH or 0.5 M HC1 and diluted to the desired
concentration with physiological saline.
TNF was produced as described previously (Ha et al
1985a). Groups of at least 10 mice were infected intravenously
with 10 4 Listeria in 0.2 ml saline or injected intraperitoneally
with 0.875 mg C. Parvum. Twenty-five ug LPS in 0.2 ml saline
were, injected intravenously into mice 5 days after Listeria
Infection or 10 days after C. Parvum treatment. Anti-
Inflammatory drugs were administered 1 hr prior to LPS Injection.
The mice were bled from subclavian vessels 2 hr after LPS
injection. The sera were pooled, filter-sterilized, heated at
°
56o C for 30 min and stored frozen at -20 C until use. Control
sera were obtained from mice Injected with Listeria or C. Parvum
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only. TNF titre was determined as described in chapter Three
“Materials and Methods”.
In all experiments, animal mortality was monitored after
LPS injection for 48 hr.
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RESULTS
Initially, consideration was given to the appropriate
experimental protocol to effectively examine the possible effects
of anti-inflammatory drugs on TNF release and LPs-induced
mortality. In particular, the appropriate time schedule, dosage
and route of administration of the drugs were deemed pertinent.
Preliminary experiments established the following regimen to be
optimal: Drugs were administered by oral intubation 1 hr or 2 hr
before LPS, or intravenously 30 min before LPS Injection.
Effect of indomethacin, phenylbutazone and acetyl-
salicylic acid on the protection of Listeria infected mice
against endotoxin shock was shown in Fig. 5.1. Mice without
anti-inflammatory drugs treatment showed the lowest percentage of
survival and all died 48 hr post-administration of LPS.
Indomethacin exhibited best protection for Listeria-infected mice
against endotoxin shock, about 40% of mice remained survived 48
hr post-administration of LPS. Table 5.1 showed the effect of
oral administration of acetylsalicylic acid, indomethacin and
phenylbutazone on the LPS-Induced release of TNF and mortality of
Listeria-infected and C. Parvum-injected mice 2 hr after LPS
injection. Mice were treated with one of these drugs at the
indicated dose 1 hr before LPS challenged protected the animals.
The* serum TNF titre was not affected by these drugs. Table 5.2
showed the effect of different routes of administration of anti-
inflammatory drugs on the LPS-induced release of TNF in Listeria-
infected mice 2 hr after LPS injection. Seen in conjunction with
Table 5.1, it was quite clear that both intraperitoneal and
intravenous injection were as effective as oral intubation in
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suppressing animal mortality without affecting TNF production.
The sucess rate of the subcutaneous route in reducing animal
death, however, was much lower.
Effect of oral administration of different amounts of
sulindac on the LPS-induced mortality of Listeria-infected mice
was shown in Fig. 5.2. The percentage of survival of mice under
treatment were monitored at different intervals after LPS
injection. Listeria-infected mice began to die 1 hr after LPS
injection. For mice without sulindac treatment, about 50% died
at 2 hr after LPS injection and all died at 24 hr post- injection.
For mice treated with different doses of sulindac exhibited
different degree of protection against LPS shock. As indicated
in Fig. 5.2, better effects of treatment on survival were
observed at medium doses namely 0.8, 1.0 mg/ mouse with 1.0 mg/
mouse the best in which nearly 70% of mice remained survived 48
hr post-administration of LPS, poor effects were observed when
mice were treated with small dose (0.375 mg/ mouse) or larger
dose (1.25 mg/ mouse). The serum TNF titre was not affected by
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Fig. 5.1 Effect of non-steroidal anti-inflammatory drugs
on the protection of Listeria-infected mice against
endotoxin shock. Groups of 15 mice were injected
intravenously with 104 Listeria 5 days before experiment.
Mice were received orally 3mg acetylsalicylate or
2.1mg indomethacin or 1.2mg phenylbutazone
1 hr before challenged with 25ug LPS. Mice without drugs






Table 5.1 Effect of anti-inflammatory drugs on TNF production and LPS-induced mortality of Listeria
infected mice and C. Parvum-injected mice
ListeriTreatment of mice C. Parvum
Listeria infection or Drug Serum TNF titre Percent Serum TNF titre Percent
mortality mortalityC. Parvum injection
50 0 50 0
1370+540 50 1650+570 60
Acetylsalicylate 50 0 50 0
Acetylsalicylate 1550+630 0 1750+250 10
Indomethacin 50 0 50 0
Indomethacin 1470+350 0 1490+440 10
Phenylbutazone 50 0 N.D. N.D.
Phenylbutazone 1390+570 0 N.D. N.D.
Groups of 20 mice were injected intravenously with 104 Listeria 5 days or injected
intraperitoneally with 0.875 ing C. Parvum 10 days before experiments. Animals received
orally 3 mg acetylsalicylate or 2.1 mg indomethacin or 1.2 mg phenylbutazone 1 hr before
being challenged with 25 ug LPS.
TNF titre was determined from sera pooled from 10 mice per group. Data are expressed as
mean ± SEM of three independent experiments.
Mortality was determined 2 hr after LPS injection. N.D.- Not determined.
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T able 5 . 2 E ffect of different routes of drug administrationon TNF




L isteria infection D rug R oute S erum TNF titre mortality
5 0 1 0
1 9 8 0 ±5 5 0 7 0
A cetylsalicylate . p . 2 1 5 0 ±5 6 0 2 0
A cetylsalicylates . c . 1 7 9 0 ±4 8 0 4 0
I ndomethacin i . p . 2 0 2 0 ±4 4 0 1 5
3 5I ndomethacin s . c . 1 8 9 0 ±3 8 0
I ndomethacin i . v . 2 0 7 0 ±6 6 0 2 0
G roups of 2 0 mice were injected intravenouslywith 1 0 4
L isteria 5 days before experiments. A nimals received 3 mg
acetylsalictlate or 2 . 1 mg indomethacin intraperitoneally
( i . p . ) or subcutaneously( . c . ) 1 hr beforeLPS injectionor
intravenously( i . v . ) 3 0 min before LPS injection.
TNF titre was determinedfrom sera pooled from 1 0 mice per
group . D ata are expressedas mean ± SEM of three independent
experiments.
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Fig. 5.2 Effect of sulindac on the time course of
mortality of Listeria-infected mice after LPS injection.
For experimental details, see legend of Fig. 5.1. The
percentage survival of Listeria-infected mice receiving
no treatment and different dose of sulindac
,0.375mg/mouse 0.625mg/mouse 0.8mg/mouse
1.0mg/mouse 1.25mg/mouse were





Table 5.3 Effect of different dose of sulindac on the TNF production
TNF activity
0.375 mg/mouse 300 - 500
0.375 mg/mouse 300 - 500
0.800 mg/mouse 300 - 500
1.000 mg/mouse 300 - 500
300 - 5001.250 mg/mouse
0.0 mg/mouse (control) 300 - 500
Mice were injected intravenously with 104 Listeria 5 days
before experiments. Animals received different doses of
sulindac orally 2 hr before LPS injection.




Bacteria have been tested as anti-tumour agents
extensively in animals and sometimes in human cancer patients,
especially in the early 1900's. The clinical results obtained
have been generally encouraging and occasionally remarkable. The
active principle has been identified as a lipopolysaccharide
(LPS) which exerts its anti-tumour effect, at least in part,
through the induced production of tumour necrosis factor (TNF)
(Shier 1985). Thus, mice pretreated with Pseudomonas vaccine and
challenged with LPS release TNF with accompanying tumour
regression in situ (Kiger et al 1980). However, animals so
primed and challenged showed a high rate of mortality as a
consequence of the many pathological effects induced by LPS. The
toxic effects of LPS limited its use in the treatment of human
cancer. A pronounced pathological effect induced by LPS is the
disturbance homeostasis of prostaglandins (Wise et al 1979). It
has been reported that LPS or lipid A can act on factor XII (ire
clotting system), platelets and leukocytes (Nowotony 1985). Any
one or all of these interactions lead to thrombin formation.
Prostaglandin and thromboxane synthesis Is Initiated In platelets
by thrombin (Bell 1979). Cook et al (1980) showed that endotoxirt
shock was mediated by thromboxane A2. It Is therefore reasonable
2
to study the effect of depression of endogenous prostaglandins
such as thromboxane A on the mortality of endotoxir shock during
2
the production of TNF in vivo. Certain anti-inflammatory drugs
have been shown to alleviate the symptoms of endotoxin shock
(Erdos et al 1967; Goodrum et al 1978). Acetylsalicylic acid
(aspirin) inhibits prostaglandin synthesis by inhibiting cyclo-
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oxygenase and endoperoxidase activity (Higgs et al 1983; Ferreira
et al 1971). Inhibition of thromboxane A production reduces
2
the sensitivity of blood vessels to the effects of circulating
adrenaline and non-adrenaline. Phenylbutazone can inhibit the
generation of C5a of the complement system (Minta et al 1983).
Histamine released from activated complement system can stimulate
the prostaglandin synthesis (Roitt et al 1985). It seems that
endotoxin induces prostaglandin synthesis through a variety of
ways and drugs with various inhibition effects on prostaglandin
synthesis have better protection of animals against endotoxin
shock. It has been reported that sulindac and tndomethacin
inhibit prostaglandin synthesis by both complement system (Minta
et a1 1983) and cyclo-oxygenase (Higgs et al 1983). It is
therefore reasonable to note that these two non-steroidal anti-
Inflammatory drugs have better protection for Listeria-infected
mice against endotoxin shock (Fig. 5.1; and Fig. 5.2). Among
different anti-inflammatory drugs under tested, our preliminary
results indicated that sulindac is the best candidate for
preventing endotoxin shock. Studies of different doses of
sulindac on TNF production and LPS lethality in mice primed with
Listeria monocytogenes were then carried out. It was found that
the optimal dose of sulindac was about 1 mg/ mouse (i.e. 29 mg/
kg- body weight) in which nearly 70% of mice remained survived
after 48 hr of LPS Injection (Fig. 5.2). Higher dose of sulindac
may have a toxic effect on the animals. Indomethacin,
phenylbutazone and acetylsalicylic acid exhibited nearly
complete protection for Listeria-primed mice against endotoxin
shock 2 hr post-administration of LPS. However, mice died
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gradually and at 48 hr after LPS injection, only about 40% of
mice remained survived in indomethacin-treated group, about 10%
in both phenylbutazone and acetylsalicylic acid- treated groups.
It should be noted that in these four anti-inflammatory drugs-
treated animals, the TNF titre (being assayed 2 hr after LPS
injection) remained relatively unchanged as compared with that of
LPS injected bacteria-primed group.
We hoped to dissociate the beneficial effects of LPS from
the pathological effects and examined the effect of
acetylsalicylic acid, indomethacin, phenylbutazone, and sulindac
on TNF production and LPS lethality in mice primed with Listeria
monocytogenes or C. Parvum. The results showed that all four
drugs protected the animals partially against the lethal effect
of LPS but do not affect the ability of animals to produce TNF
(Table 5.1; Table 5.2; and Table 5.3). Mechanism of these drugs,
especially sulindac which has the highest effectiveness, on the
protection of endotoxin shock of bacteria-primed mice during TNF
production should be worked out. The way is open for combining
drugs which regulate vasoactivity in the treatment of endotoxin
shock during the course of TNF production.
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CHAPTER SIX
Effect of mannoheptulose on the production of
Tumour Necrosis Factor and li popolysacchar ide
induced- mortality in mice
INTRODUCTION
It has been shown that sera from animals injected with
bacteria followed by endotoxin administration contained tumour
necrosis factor (TNF) activity (Carswell et al 1975 Old 1985).
However, it is impossible to induce TNF release in tumour--beari.ng
animals in order to cure tumour since administration of endotoxin
may render the host inflammation( as described in Chapter 5),
hypoglycaemia and more seriously even convulsion and death (Lang
et al 1985ab). It is of clinical interest to find methods for
the production of TNF in experimental animals without eliciting
endotoxin shock.
It is generally accepted that the endotoxin induced hypo-
glycaemia in experimental animals are mediated by insulin
(Buchanan et al 1976 Witek-Janusek et al 1983). Endotoxin can
even induce insulin sensitivity (Shands et al 1971) and lead to
more severe lethality (Shands et al 1969) in BCG-infected mice.
As far as TNF production and endotoxin shock are concerned,
Satomi et al (1985) found that insulin injection to P. acnes-
primed mice prior to endotoxin injection caused a marked decrease
in TNF production and a more severe endotoxin shock. Insulin
seems to play an important role in precipitating death in
bacteria-primed animals. It is therefore reasonable to study the
effect of depression of endogenous insulin secretion on the
mortality of endotoxin shock during the production of TNF In
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vivo. It has been reported that mannoheptulose can seletively
and reversibly depress insulin secretion in vivo (Simon et al
1972) and endotoxin shock lethality is significantly reduced in
rats under mannoheptulose treatment (Buchanan et al 1976). To
clarify the role of insulin in endotoxin shock and TNF
production, the effects of mannoheptulose, streptozotocin and
fasting on the mortality and TNF production in Listeria




Male ICR strain of mice, about 35 g body weight, were
used. Listeria monocytogenes was cultured in tryptic soy broth.
Bacteria used for infection were obtained from overnight
cultures. The endotoxin used in all experiments was
lipopolysaccharide W. from Escherichia coil, serotype 0127:B8
(LPS) which was purchased from sigma. D-mannoheptulose from Sigma
was dissolved in phosphate buffer saline, pH 7.4 (PBS) and
adjusted to the desired concentration. Streptozotocin and
insulin purchased from Sigma were dissolved in 0. 1 M citrate
buffer, pH 4.2 and adjusted to the physiological pH 7.4 before
injection.
TNF was produced as described in Chapter Three "Materials
and Methods". Groups of at least 20 mice were infected
3
intravenously with 5 x 10 Listeria in 0.2 ml PBS. Twenty-five
ug LPS In 0.2 ml saline were injected intravenously into mice 5
days after Listeria infection. To study the effect of
mannoheptulose treatment, different concentrations of
mannoheptulose were injected subcutaneously to mice 1 hr prior toy
LPS administration.
In diabetic group, mice were injected intraperitoneally
with streptozotocin (6.6 mg/mouse) to induce diabetes permanently
three days before Listeria Injection. Different concentration of
insulin were applied to rescue the mice from diabetes by daily
subcutaneously injection from the day when Listeria were
injected. Overnight fasting of mice was conducted by removing
the food from the cages on the evening prior to the experiment.
The mice were bled from subclavian vessels 2 hr after LPS
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injection. The sera were pooled (at least 6 mice). one part of
the sera was used to determine TNF activity. For TNF assay, the
°
sera were filter-sterilized, heated at 56 C for 30 min and
°
stored frozen at -20 C until use. TNF titre was determined as
described in Chapter three Materials and Methods.
The other part of sera was used to estimate the glucose
and insulin contents. Serum glucose was assayed with glucose kit
510 purchased from Sigma. Radioimmunoassay of serum insulin was
performed with a radioimmunoassay kit (Amersham, code I.M. 78 or
Dainabot No.1205-04) according to the manufacturer's manual,
125
using I-labelled insulin and human insulin standards.
In all experiments, animal mortality was monitored after
LPS challenged for 48 hr.
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RESULTS
A) Change of serum glucose and insulin during TNS production:
The nature of the carbohydrate metabolic response of mice
to LPS depends on the dose of LPS and the time elapsed after LPS
administration. Fig. 6.1 showed the time course of serum glucose
level after the injection of 25 ug LPS. Mice primed with
Listeria monocytogenes were more sensitive to LPS. As depicted
in Fig. 6.1, injection of LPS to such mice showed a short period
of hyperglycemia from 0 to 30 min after LPS injection and lasted
for a long time of hypoglycemia from 0.5 to 2.0 hr. Serum
insulin level was also monitored in Listeria-primed mice during
this period after LPS injection. As showed in Fig. 6.2, mice
primed with Listeria monocytogenes and challenged with LPS showed
a drastic increase of insulin level after 1 hr of LPS injection.
The peak occurred at about 1.5 hr after LPS administration.
B) TNF and mortality of Listeria-primed mice challenged with
LPS under conditions of different serum insulin levels:
To study the effect of insulin on TNF production and
mortality of Listeria-infected mice, three methods were applied
to change serum insulin level during the course of TNF
production. These methods were fasting, permanent induction of
diabetes by streptozotocin, and temporary suppression of insulin
secretion by mannoheptulose.
As showed in Fig. 6.3, overnight fasting could partially
protect Listeria-infected mice against endotoxin shock. As
expected, fasting caused lower glucose content in mice (Table
6.1). LPS could elicit an increase in insulin content in non-
fasting group but not in fasting group and there was no
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significant change in TNF titre between these two groups (Table
6.1).
In order to further characterize the role of insulin in
TNF production and mortality, mice were induced diabetes by
streptozotocin injection with or without exogenous insulin
treatment prior to Listeria and LPS administration. Control mice
were primed with Listeria and challenged with LPS. The results
of survival studies were shown in Fig. 6.4 and Table 6.2. A
descending order of percentage of survival rate from diabetes
group, diabetes plus exogenous insulin treatment group, to
control group were observed. This descending order of percentage
of survival rate was inversely proportional to the serum insulin
level shown in Table 6.2. Highest glucose level was observed in
diabetic group while exogenous insulin decreased the serum
glucose in diabetic group to the lowest as compared with the
other groups. There was no significant change in TNF activity
among these (groups.
C) Effect of mannoheptulose on TNF production and mortality
of Lister ia-infected mice challenged with LPS:
From the above experiments, it seems reasonable to
postulate that the survival of Listeria--primed mice can be
enhanced by lowering the serum insulin level. But it is not
practical to use streptozotocin to treat patient clinically.
Mannoheptulose may be a suitable candidate in this aspect since
it suppresses insulin secretion temporarily. Fig. 6.5 shows the
effect of subcutaneous administration of different amounts of
mannoheptulose on the LPS-induced TNF release and mortality of
Lister ia-infected mice. Treatments of such mice with
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mannoheptulose at various doses 1 hr prior to LPS administration
did not affect the TNF production. The TNF titres produced in
the control and mannoheptulose-treated groups ranged between 300
to 500. However, the percentage of survival of mice at 24 hr of
LPS postadministration varied with the doses of mannoheptulose
injected. The optimal dose for the maximum alleviation of LPS-
induced lethality was 300 mg/Kg body weight, by which 50%
survival was obtained.
To confirm the relationship between mortality and
mannoheptulose dose, the percentage of survival of mice under
treatments were monitored at different intervals after LPS
injections (Fig. 6.6). Listeria-infected mice began to die 2 hr
after LPS injections. For mice without mannoheptulose treatment,
about 50% died at 4 hr after LPS Injection and all died at 24 hr
after LPS injection. For mice treated with different doses of
mannoheptulose exhibited different degree of protection against
LPS shock. As indicated in Fig. 6.6, better effects of treatment
on survival were observed at medium doses, namely 200, 300, and
500 mg/Kg with 300 mg/Kg the best; poor effects were observed
when mice were treated with smaller dose (120 mg/Kg) or larger
doses (720 and 1000 mg/Kg).
Since it has been reported that mannoheptulose can
depress insulin secretion transiently in experimental animals
(Simon et al 1972), the glucose and insulin level in the sera of
Listeria-infected mice at 3 hr after different doses of
mannoheptulose injection (i.e. at 2 hr after LPS injections) were
measured. Fig. 6.7 showed that the serum glucose concentration
has dropped to 28 mg/100ml in Listeria-infected mice challenged
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with LPS. Mannoheptulose treatment alleviated the hypoglycemia
condition, as expected. When the mice were treated with
mannoheptulose at 200 mg/Kg or above, the glucose levels
increased to 70 - 100 mg/100ml. The insulin levels of mice were
also determined. Mannoheptulose at doses larger than 200 mg/Kg
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Fig. 6.1 Time course of serum glucose after LPS
injection. Groups of 10 mice were injected
intravenously with 5 x 103 Listeria and after 5
days such mice were challenged intravenously with
25 ug LPS. Serum was pooled from such mice at
different time post-administration of LPS. Data
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Fig. 6.2 Time course of serum insulin after LPS
injection. The serum insulin levels of mice
treated as decribed in legend of Fig. 6.1 were
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Fig. 6.3 Effect of fasting on the lethal effect of LPS
in Listeria-primed mice. Groups of 18 mice were injected
intravenously with 5 x 103 listeria and 5 days later such
mice were injected intravenously with 25 ug LPS. For
fasting group food was removed 20 hr before LPS
injection while in non-fasting group food was not
removed. Percentage of survival were determined by
observed death of mice during 48 hr after LPS injection.
%OFSURVIVAL
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Table 6.1 Effect of fasting on TNF production and serum glucose and
insulin levels in Listeria-orimed mice challenged with L2S
Insulin TNF titreGlucose
(uu/ml)(mg/100ml)
39.0 + 1.279.62 + 2.54Control
37.0 + 1.4 300 - 50034.30 + 2.02Fasting
300 - 50053.5 + 3.553.06 + 2.76Non-fasting
For experimental details, see legend of Fig. 6.3. Sera were
obtained from 8 mice per group 2 hr after LPS injection.
Sera were pooled and the glucose, insulin content and TNF
titre were determined.
Control group consisted of mice receiving Listeria only.
Data of serum glucose are expressed as mean + SEM of three
different experiments.
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Fig. 6.4 Effect of diabetes on the lethal effect of LPS
in Listeria-primed mice. Groups of 18 mice were induced
to be diabetes by streptozotocin injection
intraperitoneally (6.6 mg/mouse). 5 x 103 Listeria were
injected intravenously to such mice 3 days after induction
of diabetes. For diabetes plus exogeneous insulin treated
group(——), mice were injected subcutaneously with
insulin (3 I.U./day) dialy after induction of diabetes
till 1 hr before LPS injection. For diabetes group('
), mice were injected subcutaneously with citrate buffer
dialy after induction of diabetes. Five days after
Listeria infection, such mice were injected intravenously
with 25 ug LPS. For control group (●――●), mice were
primed with Listeria and then challenged subsequently with
LPS. Percentage of survival were determined by observing
death of mice after 48 hr of LPS injection.
Table 6.2 Effect of streotozoiocin induced-diabetes on TNF production






i. LN£ tl LxS
Control 53.06+ 2.76 52.D 3.5 300- 500
Diabetes 243.08+ 5.76 6 300- 500
Diabetes+Insulin 8.96+ 2.88 35.0+ 2.8 300- 500
For experimental details, see legend of Fig. 6.4. Sera were
obtained from 8 mice per group 2 hr after LPS injection.
Sera were pooled and the glucose, insulin content and TNF
titre were determined.
Control group consisted of Listeria-primed mice challenged
with LPS.
Data of serum glucose are expressed as mean+ SEM of uhree
different experiments.
Data of serum insulin are expressed as mean+ SEM of two
different experiments.
MANNOHEPTULOSE (mgKg)
Fig. 6.5 Effect of mannoheptulose on TNF production
and LPS-induced mortality of Listeria-infectea mice.
Groups of 20 mice were injected intravenously with 5
x 10 Listeria 5 days before experiment. Mice were
injected with different doses of mannoheptulose
subcutaneously 1 hr before being challenged with 25
ug LPS. TNF titre(•—•) were determined from sera
pooled from 5 mice per group 2 hr after LPS
injection. Percentage of survival of
List eria-infec ted mice() were determined by
observing death of mice after 24 hr of LPS
injection. Data are expressed as mean+ SEM of
three different experiments.
TIME AFTER LARS INJECTION(hr)
Fig.6.6 Effect of mannoheptulose on the time course of
mortality of Listeria-infected mice after LPS injection.
For experiental details, see legend of Fig. 6.5. The
percentage survival of Listeria-infected mice receiving
no treatment





Fig. 6.7 Effect of mannoneptulose on the serum glucose and
insulin levels in Listeria-infected mice challenged with
LPS. For experimental details, see legend of Fig. 6.5.
Sera were obtained from 5 mice per group after LPS
injection (i.e. at 3 hr after mannoheptulose injection).
Serum glucose(—) and insulin(•—•) were determined as
described in text. Data of serum glucose are expressed as
mean+_ SEM of three different experiments and data of serum
insulin are average of two experiments.
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DISCUSSION
Bacteria have been tested and used as anti-tumour agents
extensively in animals and sometimes in human cancer patients,
especially in early 1900's (Shalaby et al 1986). The active
principle has been identified as endotoxin which is a complex
l ipopolysacchar ide (LPS) on the bacterial cell membrane. LP S
exerts its anti-tumour effect, at least in part, through the
induced production of tumour necrosis factor (TNF) (old 1985).
The Injection of LPS to animal and man produce a wide variety of
hemodynamic and metabolic alternations. LPS affects the
cardiovascular status of the animal, resulting in systemic
hypotension and reduction of cardiac output (Baghy et al 1980).
It also alters the glucose homeostasis of animal, resulting in a
prominent and transient hyperglycemia followed by a hypoglycemia
(Lang et al 1985ab). An early hyperglycemia is due mainly to
hepatic glycogen depletion and gluconeogenesis while the later
hypoglycemia is due to a combination of depression of hepatic
gluconeogenesis and enhancement of peripheral glucose use
(Figlewicz et al 1978). Glycogen depletion is induced by
endotoxin which activates the membrane-bound enzyme,adenylate
cyclas (AC) (Gimpel et al 1974), which in turn activates glycogen
phosphorylase. Depression of hepatic gluconeogenesis and
enhancement of peripheral glucose use may involve the altered
insulin secretion. For medium dose of endotoxin, the rate of
glucose appearance (Ra) exceeds the rate of glucose disappearance
(Rd) in the early phase of endotoxin injection, resulting in an
early hyperglycemia. The later hypoglycemia results from the
rate of glucose appearance (Ra) less than the rate of glucose
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disappearance (Rd) which is caused by endotoxin induced insulin
sensitivity (Shands et al 1969) or insulin-like activity of
endotoxin (Witek-Janusek et al 1983). For relatively large dose
of endotoxin, the early hyperglycemia may be too short to be
measured under traditional experimental conditions. Moreover,
in the present study, the Listeria-printed mice were fmmore
sensitive to endotoxin. An early hyperglycemia occurred about 10
min after LPS injection and a long period of hypoglycemia
developed subsequently (Fig. 6.1). This toxic effects of LPS
limit its use in the treatment of human cancer.
For the production of mouse TNF, mice were primed with
BCG (Carswell et al 1975), or C. Parvum (Green et al 1977; Satomi
et al 1985) or Listeria (Ha et al 1985a) and challenged several
days later with LPS. However, mice so primed and challenged
showed a high rate of mortality. This endotoxin shock is
characterized by a profound, progressive hypoglycemia and a
marked hyperinsulinism in response to a glucose stimulus (Filkins
et al 1977). As indicated in Fig. 6.2, Listeria-primed and LPS
(25 ug) challenged mice exhibited insulin peak at 1.5 hr after
LPS injection. It has. been reported that diacylglycerol
increases rapidly during insulin action (Farese et al 1985) and
arachidonate is shown to be derived from diacylglycerol (Bell et
al 1979). leading to prostaglandin such as thromboxane A
2
synthesis and thromboxane A is a mediator of endotoxemia (Cook
2
et al 1980). It is therefore reasonable to treat the mice during
the course of TNF production with a drug which can antagonize
insulin action with the hope of alleviating the lethality due to
endotoxin shock without affecting the ability of the animals to
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produce TNF. Fasting which was can depress insulin secretion
(Table 6.1) has been tested. Overnight fasting could partially
protect Listeria-primed mice against endotoxin shock as compared
with non-fasting group (Fig. 6.3). There was no significant
change in TNF titre between these groups (Table 6.1). In fasting
treatment, glycogen may already be depleted so that
administration of endotoxin to such mice cannot further develop
an early hyperglycemia which in turn stimulates the secretion of
insulin. On the other hand, the non-fasting mice can produce an
early hyperglycemia due to the action of endotoxin on glycogen
breakdown. This pulse increase in glucose will stimulate the
secretion of insulin probably leading to a higher rate of
mortality.
The above results indicated that lowering the serum
insulin level can alleviate the lethal effect of endotoxin
without changing TNF titre. Therefore, complete depression of
insulin in these animals have been tried. Mice induced diabetes
by streptozotocin showed high percentage of survival rate (Fig.
6.4). Injection of exogeneous insulin to such mice decreased the
percentage of survival rate. Diabetic mice also exhibited the
highest glucose level compared with other groups (Table 6.2).
However, this high glucose could not stimulate the insulin
secretion because beta-cells in the diabetic group have been
destroyed by streptozotocin. Exogeneous insulin could decrease
serum glucose level with suppression of percentage of survival
rate. TNF titre ranged from 300 to 500 In these groups without
any significant change.
The diabetic mice had a higher percentage of survival
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rate compared that of mice under fasting treatment (Fig 6.3 and
Fig. 6.4). However, streptozotocin induced diabetes cannot be
used in patients because streptozotocin may destroy beta-cells
permanently. In this connection, mannohe-ptulose which can
transiently depress insulin secretion was tested. Twenty-five ug
LPS administered to Listerla-pr imed mice caused 50% death at 4 hr
and 100% death at 24 hr post-administration (Fig. 6.6). This was
consistent with the report of Satomi et al (1985) who showed that
high mortality were observed in P. acnes-primed mice following
administration of small doses of LPS. The serum glucose levels
increased from 28 mg/100ml to 70- 100 mg/100ml when Listeria-
primed mice were injected with mannoheptulose at 200 mg/Kg or
above, 1 hr prior to LPS Injections (Fig. 6.7). Serum insulin
decreased as the dose of mannoheptulose increased (Fig. 6.5).
Mannoheptulose treatment did not affect the ability of the mice
to produce TNF. The TNF titre produced in the control and
mannoheptulose-treated groups ranged between 300 - 500. It
should be noted that even at the optimal dose of mannoheptulose
(300 mg/Kg), only 50% survival at 24 hr after LPS administration
were observed. Fig. 6.6 showed the changes of survival under
different concentrations of mannoheptulose respective to time
after LPS injection. It is clear that mannoheptulose injected at
200, 300, and 500 mg/Kg could partially protect endotoxin shock
of mice whereas higher dose of mannoheptulose might even exert
certain toxic effect on mice.
Up to present, no procedure has been reported to
dissociate the beneficial effect of LPS for producing TNF from
the pathological effect of LPS for eliciting hypoglycemia and
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death. In the present investigation, though the insulin
homeostasis of LPS-challenged mice could be normalized by
mannoheptulose injection without affecting TNF production, only
partial protection, up to 50% protection at optimal dose at 24 hr
of LPS post-administration, was observed. Besides producing
hyperinsulinism, LPS also causes cardiovascular derangement and
leads to death in animals (Bagby et al 1980). Administration of
non-steroidal anti-inflammatory drugs partially protected the
Llsteria-primed mice against the lethal effect of LPS without
affecting the ability of animals to produce TNF (Chapter Five).
Hence it is of interest to combine the administration of
mannoheptulose and anti-inflammatory drugs to determine whether
it can completely protect the bacteria-primed animals from
endotoxin shock without affecting TNF production.
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CHAPTER SEVEN
Combination anti-inflammatory drugs with
insulin suppression drugs against endotoxin shock
INTRODUCTION
One of the most beneficial action of endotoxin has been
their capacity to elicit TNF into serum of animals sensitized to
immunopotentiators such as bacillus Calmette - Guerin (BCG)
(Carswell et al 1975) or Corynebacterium Parvum (Green et al
1977), or Listeria (Ha et al 1985a). Endotoxin exerts its anti-
tumour effect, at least in part, through the induced production
of tumour necrosis factor (TNF) (old 1985). However, endotoxin
(LPS) is highly toxic for animals primed with these micro-
organisms, possibly as a consequence of the increased production
and release of prostaglandins causing inflammation as well as
insulin causing hypoglycaemia. These toxic effect of LPS limit
its use in the treatment of cancer in vivo. on the other word,
it is impossible to induce TNF release in tumour-bearing animals
in order to cure tumours. However, previous studies in chapter 5
and 6 have shown that certain non-steroidal anti-inflammatory
drugs such as acetylsalicylic acid, phenylbutazone,indomethacin,
and sulindac or insulin suppression drugs such as mannoheptulose
can partially protect Listeria-infected mice against endotoxin
shock without affecting the ability of animals to produce TNF.
In view of the therapeutic potential of TNF, it is interested in
studying whether the combined administration of mannoheptulose
and anti-inflammatory drugs can completely protect the bacteria-




Male ICR strain of mice, about 35 g body weight, were
used in all experiments. D-mannoheptulose (45mg/ml), acetyl-
salicylic acid (15mg/ml) and sulindac (5mg/ml) were dissolved in
water. The solutions were adjusted to pH 7.0 with 0.5 M NaOH or
0.5 M HC1.
Groups of at least 24 mice were injected intravenously
4
with 10 Listeria in 0.2 ml. Twenty-five ug LPS in 0.2 ml saline
were injected intravenously into mice 5 days after Listeria
infection. To study the effect of combined treatment, animals
received 3 mg acetylsalicylic acid and 9 mg mannoheptulose
subcutaneously 1 hr before LPS injection or received 9 mg
mannoheptulose subcutaneously and 1 mg sulindac orally, 1 hr and
2 hr respectively before LPS injection. Animals in control group
did not receive any drug. The mice were bled from subclavian
vessels 2 hr after LPS injection. The sera were pooled, filter-
sterilized, heated at 56°C for 30 min and stored frozen at -20°
C until use. Normal sera were obtained from mice Injected with
Listeria only. TNF titre was determined as described in chapter
three "Materials and Methods".
In all experiments, animal mortality was monitored post-
administration of LPS for 48 hr.
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RFSULTS
Fig. 7.1 showed the effect of combined treatment of
acetylsalicylic acid with mannoheptulose on the mortality of
Listeria-infected mice after LPS challenged. The combined
treatment showed the highest protection of Listerla-infected mice
against endotoxin shock. About 60% of such mice were survived at
48 hr after LPS treatment. For control group, mice without
receiving any drug showed the lowest percentage of survival and
all died at 48 hr after LPS Injection. Mice received
mannoheptulose or acetylsalicylic acid both showed about 45%
survival. The serum TNF activity was not affected in all cases
(Table 7.1). Enhancement of survival of mice were observed when
sulindac was used in conjunction with mannoheptulose as a
combined treatment (Fig. 7.2). Nearly 80% of mice remained
survived in combined treated group, whereas only about 60% of
mice survived in groups treated with individual drug. The TNF
titre remained unchanged in these groups (Table 7.2). Seen in
conjunction with Fig. 7.1, it was quite clear that the combined
treatment of mannoheptulose with anti-inflammatory drugs such as
acetylsalicylic acid or sulindac was effective than that treated
with individual drug in the protection of Listeria-infected mice
against endotoxin shock without affecting the ability of animal
to produce TNF. However, it should be noted that the protection
of Listeria-infected mice against endotoxin shock by combined
treatment was not complete.
TIME AFTER LPS INJECTION (h r]
Fig. 7.1 Effect of combined treatment of mannoheptulose and
acetyIsalicy1ic acid on the mortality of Listeria-infected
mice after LPS injection. Groups of 24 mice were injected
intravenously with 10 Listeria 5 days before experiments.
Mice received orally 3 mg acety Isalicy lie acid(), or
subcutaneously 9 mg mannoheptulose(—) 1 hr before being
challenged with 25 ug LPS. Mice (o a) also received
combined treatment of mannoheptulose and acetyIsalicylie
acid. The control mice(••) received Listeria and LPS
only. Percentage survival of Listeria-infected mice were
monitored after LPS injection for 48 hr.
Table 7.1 Effect of combined treatment or .Tanncheptulcse and acetylsalicylic acid





Control (without drug treatment
-25CC
- 2 5 0 C
-250C
-? nr
For exDerimental details, see leaend of Fig. 7.1
• Sera for TNF assay were collected from 8 mice per group 2
hr after LPS injection.
TIME AFTER LPS INJECTION (hr)
Fig. 7.2 Effect of combined treatment of mannoheptulose and
sulindac on the mortality of Listeria-infected mice after LPS
injection. 24 mice in each group were injected intravenously
with 10 Listeria 5 days before experiments. Mice received
subcutaneouslv 9 mg mannoheptulose (C O), or orally 1 mg
sulindac() 1 hr, 2 hr respectively before being
challenged with 25 ug LPS. Mice (A A) also received combined
treatment of sulindac and mannoheptulose. The control mice(
••) received Listeria and LPS only. Percentage survival of
Listeria-infected mice were monitored after LPS injection ror
4 8 hr.
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Table 7.2 Effect of combined treatment of mannoheotulose and suli-ndac
on TNF production in Listeria-infected mice
TNF titreTreatment
-2500




For experimental details, see legend of Fig. 7.2.




I n Chapter five and s i x, we have found that certain non-
steroidal anti-inflammatory drugs such as acetylsalicylic acid,
phenylbutazone, indomethacin and sulindac or insulin
suppression drugs such as mannoheptulose could protect Listeria-
infected or C. Parvum-primed mice against endotoxin shock without
affecting the ability of animals to produce TNF. However, the
protection by these drugs was partial and in dose dependent
manner. Large dose of anti -inflammatory drugs or mannoheptulose
cannot be administered since gastric irritation or the bleeding
tendency will occur when large amounts of anti -inflammatory drugs
such as acetylsalicylic acid (aspirin) are administered (collet
1982) and the toxic effect may appear when high dose of insulin
suppression drugs such as mannoheptulose is injected. it is of
interest to test whether the combined treatment with these two
kinds of drugs at optimal dose can completely protect bacteria-
primed animals against endotoxin shock during TNF production in
vivo. The results (Fig. 7.1 and Fig. 7.2) showed that two
combined treatments, sulindac plus mannoheptulose or acetyl-
salicylic acid plus mannoheptulose, can enhance the protection in
the animals against the lethal effect of LPS as compared with
individual treatment but do not affect the ability of animals to
produce TNF (Table 7.1 and Table 7.2). The protection by
sulindac plus mannoheptulose was even better than that of acetyl-
salicylic acid plus mannoheptulose. Nearly 80% survival of mice
were observed after 48 hr of LPS injection. This may be due to
the higher ability of sulindac than acetyl-salicylic acid to
inhibit prostaglandin synthesis in animals (Minta et al 1983).
It should be emphasized, however, that the protection is Improved
in combined treatment but no complete protection can be observed.
It implies that some biologic effects other than prostaglandin
release or glucose homeostasis induced by LPS may play a role in
the endotoxin shock. For example, it has been reported that
glucocorticoid antagonizing factor (GAF) induced by endotoxin
sensitizes mice to endotoxin lethality (Goodrum et al 1978).
CHAPTER EIGHT
Effect of lipid A, monophosphoryl lipid A, extraction methods
and strains of 1ipopolysaccharide on the production of TNF
and mortality in Listeria-infected mice
INTRODUCTION
Llpopolysaccharides (LPS or endotoxin) are part of the
outer membrane of Gram-negative bacteria. They consist of two
main components with different physico-chemical character: a
hetero-polysaccharide and a convalently bound lipid which has
been designated as lipid A (Fig. 8.1a) (Riethel et al 1975). The
polysaccharide component is composed of the O-side chain (region
I) and the core-ollgosaccharide (region II). The o-specific side
chain carries the serological specificity of LPS and the
respective bacteria. This side chain, therefore, is species
specific. The core-oligosaccharide is group-specific. Lipid A
(region III) covalently binds to 2-keto-3-deoxyoctonate (KDO) of
core-oligisaccharide. It has been reported that most of the
biological activities Induced by LPS can be directly attributed
to the lipid A (Catherine et al 1983; Luderitz et al 1973).
Lipid A contains D-glucosamine disaccharide as the backbone,
phosphate and long fatty acids as the side chain (Fig. 8.1b)
(Amano et al 1986; Catherine et al 1983). The types of fatty
acid and the positions where they attach to depend on the strain
of bacteria (Kabir et al 1978; Riethschel et al 1975).
Injection of LPS into animals induces a number of
biological effects (Kabir et al 1978; Stephen 1981). Some of
these effects are beneficial leading to increase resistance to
infections and necrosis of tumours through TNF production while
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the harmful effects lead to fever and the development of lethal
shock.
Many investigators have sought to dissociate the toxic
effect of LPS from its beneficial properties by different
methods. Morrison et al (1975) found that phenol extracted LPS
was slightly more toxic than butanol extracted LPS. Recently,
it has been reported that the kind of acyl substituerits, their
locations, and phosphorylation position in lipid A are important
for expressing the biological activities of LPS (Matsuura et al
1985 Homma et al 1985). Ribi et al (1986) showed that
monophosphoryl lipid A (MPL) was nonotoxic, but was still a
potent Immunostimulator. Monophosphoryl lipid A (MPL) lacked a
phosphate group at the C-i position of the reducing-end
glucosamine of diphosphoryl lipid A which was toxic (Fig. 8.1b).
TNF is capable of killing tumour cells in vivo and in
vitro. It was discovered by Carswell et al (1975) in the serum
of mice infected with bacillus Camette-Guerin (BCG) and
challenged subsequently with lipopolysaccharide (LPS). Later, it
was found that Corynebacteria Parvum (C. Parvum) (Green et al
1977), Plasmodia (Clark et al 1981). Mycobacterium lepraemurium
(Ha et al 1983), and Listeria monocytogenes (LM) (Ha et al 1985a)
could substitute BCG as priming agents in the production of TNF.
Up to now there has not any chemicals which can be used in the
place of LPS in TNF production. Unfortunately, animals primed
with micro-organisms are hypersensitive to lethal effect of LPS.
The usefulness of LPS in the production of TNF is therefore
severely curtailed. However, detoxification, of LPS by modifying
the toxic centre, lipid A, opens the way to dissociate the
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beneficial effects of LPS from its toxic effects. It is
therefore reasonable to study whether the lipid A derivatives
modified by different methods has the ability to produce TNF In
Listeria-infected mice without exhibiting toxic effect on them.
Fig. 8. laGeneral structure of a Salmonella lipopolysaccharide. A-D sugar residues:
Glc, D-glucose; Gal, D-galactose; GlcN, D-glucosamine; GlcNAc, V-acetyl-D-glucos-
amine; Hep, L-glycero-D-77tf770-heptose; KDO, 2-keto-3-deoxy-D-?7a7A70-octonate:
Ara N, 4-amino-L-arabinose; P, phosphate; EtN, ethanolamine;, hydroxy and
non-hydroxy fatty acids; Ra to Re, incomplete R-form lipopolysaccharides. (From
Luderitz et al., 1982, reproduced by permission of Pergamon Press.)
Fig.8.1b
R« P03H2 Dtphosphoryl Lipid A, Mol. Wt. 1797 arm
R- H Monophosphoryl Lipid A, MoL WL 1717 amu
EXPERIMENTAL
Hale ICR strain of mice, about 30- 35 g body weight,
were used in all experiments. Listeria monocytogenes was
cultured in tryptic soy broth as described previously (Ha et al
1985a). Bacteria used for infection were obtained from overnight
cultures. Corynebacterium Parvum (strain CN 6134) was obtained
from Wellcome Laboratories (Beckenham, Kent).
Lipopolysaccharide W. (LPS, Escherichia coli, serotype
0127:B8) butanol extract, phenol extract, trichloroacetic acid
(TCA) extract and 1ipopolysaccharide W. (LPS, Escherichia coli
serotype 0128:B12) phenol extract were purchased from Sigma (St.
Louis, Mo). Lipopolysaccharide (LPS, Samonella typhlmurium)
phenol extract was also the product of Sigma. Lipid A and
monophosphoryl lipid A (from Salmonella typhimuriurn) were
obtained from Ribi Immunochem. Research, Inc. Lipid A dissolved
in water containing 1% triethylamine while LPS or monophosphoryl
lipid A were dissolved in saline.
Base-hydrolysed LPS (BH-LPS) and crude lipid A were
prepared as described previously (Ha et al 1985b). Briefly, five
o
milligrams LPS was dissolved in 5 ml 0.5N NaOH and heated at 56
C for 60 min. Control LPS (BH-LPS-control) was dissolved in 0.5M
o
NaCl and treated similarly. The solution was cooled to 0 C and
precipitates that appeared were removed by centrifugation at
lOOOg for 15 min. The solution was neutralised with HCl,
o
dialysed against 3.5 liter distilled water at 4 C overnight and
lyophl1ised. Crude lipid A was prepared by hydrolysis of 1 mg
o
LPSml in 1% acetic acid at 100 C for 90 min. The hydrolysate
was centrifuged in an Eppendorf centrifuge (model 5414) for 5 min
at room temperature. The precipitate was washed twice in hot 1%
acetic acid and once with hot distilled water. This is
designated as crude lipid A. LPS used in preparing base-
hydrolysed LPS and crude lipid A was from Escherichia coll
0127:B8.
4
Groups of 20 mice were infected intravenously with 10
Lister ia or injected iritraper itoneally with 0.875 mg C_ Parvum in
0,2 ml saline. Twenty-five ug different sources of LPS, lipid A
or monophosphoryl lipid A in 0.2 ml saline or water containing 1%
triethylamine were injected intravenously into mice 5 days after
Lister ia infection or 10 days after Parvum treatment. The
mice were bled from subclavian vessels 2 hr after LPS injection.
o
The sera were pooled, filter-sterilized, heated at 56 c for 30
o
min and stored frozen at -20 C until use. Control serum was
obtained from mice Injected with Lister la only. TNF titre was
determined as described in chapter three Materials and
Methods M.
For mortality determination, mice were monitored for 24
hr after injection of different LPS preparations.
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RESULTS
It has been reported that the kind of acyl substituents
and their position in the lipid A moiety of LPS of various
strains of bacteria are important for expressing the biological
activities of LPS (Kabir et al 1978 Riethschel et al 1975
Matsuura et al 1985 Homma et al 1985). It is therefore
interesting in using LPS from different strains of bacteria to
examine their toxicity and TNF production ability In mice. LPS
from E. coil 0127:B8, E. coil 0128:B12 and salmonella
typhimurium, all extracted by phenol, were injected intravenously
into Listeria-infected mice. It was found that there was
significant difference in lethal rate among these LPS
preparations. LPS from E. cola 0127:B8 was less toxic than LPS
from E. coil 0128:B12 or Salmonella typhimurium in Listeria-
infected mice (Fig. 8.2). in contrast, there were no significant
difference in TNF titre among these three LPS treated groups
(Table 8.1).
LPS from E. cola (serotype 0127:B8) prepared by phenol
extraction (phenol-LPS), butanol extraction (butanol-LPS) or
trichloroacetic acid extraction (TCA-LPS) were injected
intravenously into Listeria-infected mice and their effects on
the mortality of mice were monitored (Fig. 8.3). It was found
that phenol-LPS and TCA-LPS were more toxic than butanol-LPS in
Listeria-Infected mice. Fifty percent of Listeria-infected mice
died about 1 hr after phenol-LPs or TCA-LPS Injection. In
contrast, the percentage of survival was higher in Listeria-
Infected mice challenged with butanol-LPS. About 40% of rilice
remained alive after 48 hr of butanol-LPS injection. With regard
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to TNF production, phenol-LPS, butariol-LPS, and TCA-LPS had
similar ability to elicit TNF into the serum of Listeria-infected
mice (Table 8.2). TNF titre ranged from 500- 1000.
In order to test whether butanol-LPS Is also less toxic
in mice challenged with other bacteria, its effect on C. Parvum-
primed mice was tested. Fig. 8.4 compared the effect of phenol-
LPS and butanol-LPS on the lethal rate of mice primed with C.
Parvum. Similar results were obtained as in Listeria-primed mice
(Fig. 8.3). Butanol-LPS was less toxic than phenol-LPS in C.
Parvum-primed mice and there was no significant difference in TNF
titre between these groups (Table 8.3).
To further study whether lipid A or carbohydrate
component of LPS exerts the lethal effect of LPS and the
eliciting effect of TNF production in Listeria-infected mice,
crude lipid A or base-hydrolysed LPS (BH-LPS) devoid of lipid A
from LPS (E. coli 0127:B8- phenol extracted) were injected
intravenously into Listeria-infected mice. It was found that BH-
LPS was less toxic to Listeria-infected mice than crude lipid A
(Fig. 8.5), the percentage of survival were 80% and 70% after 48
hr of injection respectively. LPS (without treatment) and base-
hydrolysed LPS control (BH-LPS-control, LPS treated with NaCl
instead of NaOH) showed sever toxic effect. Intact LPS Induced
the highest titre of TNF in the serum of Listeria-infected mice
(Table 8.4). Crude lipid A still retained its ability to induce
TNF release but is significant less effective than intact LPs.
BH-LPS lost its ability to elicit TNF into the serum of such
mice.
Commercial available lipid A and monophosphoryl lipid A
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from LPS (salmonella typhimurium) were also studied.
Monophosphoryl lipid A (MPL) differs from lipid A (diphosphoryl
lipid A, DPL) in that MPL lacks a phosphate group at the C--1
position of the reducing-end glucosamine (Fig. 8.1b). This
difference in structure rendered the LPS molecule a great change
in the toxicity in Listeria-infected mice (Fig. 8.6).
Monophosphoryl lipid A was less toxic than lipid A. The
percentage of survival of mice receiving monophosphoryl lipid A
at 48 hr after injection was about 67% but that of lipid A was
only 43%. For the ability to induce TNF release, monophosphoryl
lipid A retained similar ability comparing with that of lipid A
(Table 8.5). However, both lipid A molecules could produce only
less than half TNF content as compared with that produced by the
intact LPS molecule.
Fig 8. 2 20 mice were injected intravenously with 10H
Listeria in 0.2 ml saline.- Twenty-five ug phenol extracted
LPS from _E. Coli 0127:B8 (A A), E_. Coli 0128:B12(••),
or Salmonella ty phimur ium() in 0.2 ml saline were
injected intravenously into mice 5 days after
Listeria-infection. Survival was monitored for 48 hr after
LPS injection.
Table 8.1 Effect of LPS from different strains of bacteria cn the production of
TNF in Listeria-Drimed mice
T.TP+- i f- y-o
LPS (E.Coli 0127:B8-phenol)
LPS (E.Ccli 0128:Bl2-phenol)




- For experimental details, see legend of Fig. 8.2.
Sera for TNF assay were collected from 8 mice per group 2 hr after
LPS injection.
Data were expressed as range of three experimental data.
TIME AFTER LPS INJECTION (hr)
Fig. 8.3 20 mice were injected intravenously with 10 Listeria in
0.2 ml saline. 25 ug LPS from E. Coli 0127:B8 prepared by phenol
(★★), TCA(••), or butanol() in 0.2 ml saline were
injected intravenously into mice 5 days after Listeria-mfection.
Survival was monitored for 48 hr after LPS injection.
Table 8.2 Effect of LPS extracted by different methods on the production of 1235 ir
Listeria-orimed mice
TNF titre
LPS (E. Coli 0127:B8- phenol)
LPS (E. Coli 0127:38- TCA)




For experimental details, see legend of Fig. 8.3.
Sera for TNF assay were collected from 8 mice per group 2 hr after
LPS injection.
Data were expressed as range of three experimental data.
TIME AFTER LPS INJECTION (hr]
Fig. 8. 4 20 mice were injected intravenously with 0. 875 mg C.
Parvum in 0.2 ml saline. 25 ug LPS from _E. Coli 0127:B8 prepared
by phenol(••), or butanol() in 0.2 ml saline were
injected intravenously into mice 10 days after C.
Parvum—infection. Survival was monitored for 48 hr after LPS
injection.
Table 8.3 Effect of LPS prepared by phenol and butanol extraction on the production
of TNF in C. Parvum-orimed mice.
TNF titre
LPS (E. Coli 0127:B8- phenol)
LPS (E, Coli 0127:B8- butanol)
500- 1000
500- 1000
- For experimental details, see legend Fig. 8.4.
- sera for TNF assay were collected from 8 mice per group 2 hr after LPS
injection.
- Data were expressed as range of three experimental data.
TIME AFTER LPS INJECTION (hr)
Fig. 8.5 20 mice were injected intravenously with Id4 Listeria
in 0.2 ml saline. 2 5 ug Base-hyarolysed LPS(), crude lipid
A(), LPS (without treatment)(••), or Base-hydrolysed
LPS control (LPS treated with NaCl instead of NaOH, see
experimental in this chapter)() in 0.2 ml saline were
injected intravenously into mice 5 days after Listeria-infection.
Survival was monitored for 48 hr after LPS injection.
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Table 8.4 Effect of crude lipid A, colysaccharide and LPS on the production of




500- 1000Base-hydrolysed LPS- control
500- 1000LPS- without treatment
For experimental details, see legend of Fig. 8.5.
- Sera for TNF assay were collected from 8 mice per group 2 hr after LPS
injection.
- Crude lipid A, and Base-hydrolysed LPS were prepared from LPS (E.
Coli 0127:B8- phenol).
TIME AFTER LPS INJECTION (hr)
Fig. 8. 6 20 mice were injected intravenously with 104 Listeria
in 0.2 ml saline. 25 ug monophosphory 1 lipid A (O O), lipid A
(i.e. diphosphoryl lipid A) (A A), or LPS() in 0.2 ml
saline were injected intravenously into mice 5 days after
Listeria-infection. Survival was monitored for 48 hr after LPS
injection.
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Table 8.5 Effect of morcohosohcrvl lipid A, lipid A and L2S on the production of




500- 1000LPS (Salmonella typhimurium)
- For experimental details, see legend of Fig. 8_6.
- Sera for TNF assay were collected from 8 mice per group 2 hr after
LPS injection.




As mentioned in previous chapters, LPS is toxic to
experimental animals during the course of TNF production. There
are a number of Gram-negative bacterial products reported in the
literature that are less toxic (Nowotny 1983b). We examined
their effects on producing TNF in Listeria or C. Parvum primed
mice. It was found that LPS from E. cola 0127:B8 was less toxic
in Listeria-infected mice than LPS from Salmonella typhimurium or
E. cola 0128:B12 (Fig. 8.2). The difference in the lethal effect
of LPS deriving from different strain might be due to different
kind of acyl substituents and their location in LPS (Kabir et al
1978 Riethschel et al 1975) because it has been repo-r-ted that
the kind of acyl substituents, their location, and the
phosphorylation position in LPS are important for expressing the
biological activities of endotoxin (Matsuura et al 1985 Homma et
al 1985). With regard to TNF-inducing activity, these three LPS
from different strains of bacteria retained the ability to induce
TNF release in the serum of Listeria-Infected mice (Table 8.1).
However, LPS from E. coil 0127:B8 was better than LPS from E.
cola 0128:B12 or Salmonella typhimurium since the former was less
toxic than the latters.
Since Nowotny et al (1966) suggested that trichloroacetic
acid (TCA), phenol, and diethylene glycol extractions of LPS,
might chemically alter LPS structure, effects of butanol-
extracted LPS, TCA-extracted LPS, and phenol-extracted LPS from
E. coil 0127:B8 on TNF production in bacteria-primed mice were
studied. Phenol-extracted LPS was devoid of protein (Morrison et
al 1975 Sultzer 1983), protein in LPS prepared by extraction
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with TCA was designated endotoxin protein (EP) (Sultzer 1985)
while protein associated with LPS prepared by butanol extraction
was called lipid A-associated protein (LAP) (Sultzer 1983 Mcadam
et al 1978). Sultzer (1983) reported that EP differed from LAP
In several aspects even though they were both active on C3H/HeJ
spleen cells: For instance, EP can activate DNA synthesis and
polyclonal antibody in human peripheral blood lymphocytes (HPBL)
while LAP, on the other hand, cannot stimulate DNA synthesis In
HPBL. In addition, EP has less toxicity in some animal species.
Infection of LPS (from E. cola 0127:B8) prepared by phenol
extraction (phenol-LPS), TCA extraction (TCA-LPS) or butanol
extraction (butanol-LPS) into Listeria-infected or C. Parvum-
primed mice resulted In altering the lethal rate in such mice
(Fig. 8.3 and Fig. 8.4) without affecting the mice to produce
TNF (Table 8.2 and Table 8.3). Butanol-LPS was less toxic than
TCA-LPS or phenol-LPS. This result is consistent with that
reported by Morrison et al (1975) that phenol-LPS might be
slightly more toxic than butanol-LPS. This phenomenon may be
explained by the nature of lipid A-associated protein (LAP) in
the butanol extraction of LPS. LAP reduced phosphate content in
butanol-LPS (Morrison et al 1975) while endotoxin protein (EP)
might not have this ability to reduce phosphate content in TCA-
LPS. Hence, the descending order of phosphate content In these
three different methods prepared LPS are phenol-LPS, TCA-LPS, and
butanol-LPS. It has been reported that the toxic lipid A of LPS
can be converted into nontoxic form by removing the phosphate
group in lipid A (Matsuura et al 1985 Homma et al 1985 Ribi et
al 1986). The following experimental results further proved this
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to be the case. Lipid A (diphosphoryl lipid A, DPL) from
Salmonella typhimurium was more toxic than monophosphoryl lipid A
(MPL) from the same strain whereas the whole molecule of LPS from
Salmonella typhimurium with C-1 and C-4 phosphate groups in lipid
A showed highly toxicity in Listeria-infected mice (Fig. 8.6).
It is also interesting in studying whether the
polysaccharide component in LPS expresses the toxic effect on
bacteria-primed mice. Base-hydrolysed LPS (BH-LPS) (from E. coil
0127:B8), is the polysaccharide part in LPS devo id ing of lipid A,
showed only slightly toxicity (Fig. 8.5). In contrast, crude
lipid A (from E. cola 0127:88) expressed less toxicity than that
of the whole molecule of LPS (from E. coil 0127:B8) but higher
toxicity than that of BH-LPS, polysaccharide part. These results
were also consistent with those reported by Catherine et al
(1983) and Luderitz et al (1973) that most of the biological
activities induced by LPS can be directly attributed to the lipid
A but not polysaccharide component in LPS. With regard to the
ability to induce TNF release in the serum of Listeria- infected
mice, it was found that LPS whole molecule had the ability to
induce TNF release while lipid A (DPL) or monophosphoryl lipid A
(MPL) retained the ability to elicit TNF Into the serum but was
significant less effective than that of the native LPS whole
molecule (Table 8.4 and Table 8.5). BH-LPS lost the ability to
Induce TNF release. It has been reported that it is required for
the animals to have continued presence of LPS during the course
of TNF production (Gifford et al 1986). We found that (Ha et al
1985a) TNF activity declined sharply in bacteria-primed mice 3 hr
after LPS Injection. This may be due to the rapid clearance of
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LIPS from the circulation by the liver, lungs, and kidneys
(Freudenbery et al 1982 Nordstoga et al 1986). Based on above
results, a conclusion can be made that lipid A retains partial
ability to induce TNF release while the functions of
polysaccharide part may be serving a serological carrier for
lipid A to TNF producing cells, conferring solubility, optimizing
the size of micellar aggregates of LPS, and increasing the half
life of lipid A. These functions of polysaccharide have widely
been accepted (Riethschel et al 1975 Stephen 1981). It i
therefore proposed that modified LPS with monop-hosphoryl lipid A
(MPL) attached to polysaccharide is a good candidate for




Effect of recombinant human tumour necrosis factor on
transport function of cultured Ehrlich ascites tumours
INTRODUCTION
Ehrlich ascites tumour (EAT) was derived from a
spontaneous murine mammary adenocarcioma (Ehrlich et al 1905).
It was first converted from solid form into ascites form by
Lowenthal et al (1932) and carried in outbred mice by serial
Intraperitoneal passage. It has long been used as a tumour cell
model. The EAT subline in our laboratory is Ny Klein strain
which was established by Klein et al (1956). EAT can be grown in
mice and transplanted to permanent suspension culture and vice
versa. For in vivo studies, the maximal growth of tumour (about 2
9 6
x 10 cells) can be obtained 8- 9 days after 10 cells
implantation. For in vitro studies, the maximal cell density is
6
about 10 cells/ ml and the generation time is quite constant
with average length of 22 hours before reaching the growth
plateau.
The actual mechanism of action of TNF on tumour cells by
and large unknown. While TNF has been implicated in a wide
spectrum of biological activities including its indirect effect
in reducing blood supply to tumours, its immunomodulatory action
in the tumour-bearing host (Old 1985), as well as demonstrably
direct enhancement of expression of major histocompatibility
complex on tumour cells( immunol. Today,1986) and
Inhibition of HYC gene expression on promyelocytic leukemic cells
HL-60 (Kronke et al 1987), its focal point of action has not been
elucidated. Our preliminary work, using TNF-containing mouse
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serum and EAT cells, indicated that EAT is one of the most
susceptible cell lines among TNF target cells thus far examined
exposure of EAT cells to TNF-containing mouse serum for as little
as 4 hours totally abolished the transplantabi l ity of the tumour
and at the same time, the rate of glucose uptake and extent of
leucine incorporation were significantly reduced (Fung et al
1985). We have now obtained pure recombinant human TNF from
Genentech Inc. (South California, U.S.A.) in sufficient
quantities for detailed investigation. In the present thesis, we
plan to study the effect of pure recombinant human TNF on the
glucose transport system of EAT cell.
Tumour cells depend primarily on the catabolic breakdown
of glucose for the provision of energy. To maintain growth
potential, it is essential that tumour cells- should possess a
highly efficient system for the transport of glucose into the
cell and metabolize it. We (Chan et al 1983) have shown that the
ability of EAT cells to take up glucose increased progressively
during the course of tumour development and as the rate of uptake
of glucose in tumour cells rose, the surface density of glucose
carriers also increased simultaneously. We believe that this
enhancement of glucose uptake by cancer cells during tumour
growth, through increases in the number of glucose carriers,
conptitutes the primary cause of hypoglycaemia seen in patients
or experimental animals bearing tumour.
In studies concerning the chemotherapy of EAT cells, we
observed that methotrexate (Chan et al 1983), N-(phosphonacetyl)-
L-aspartate (Leung et al 1984) and interferon inducers (Fung et
al 1986) suppressed tumour growth and simultaneously suppressed
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glucose transport by decreasing the density of glucose carriers
of the tumour cell surface. Though the exact mechanism of the
actions of these anti-tumour agents on the suppression of glucose
carrier density remains a subject for further studies, our
preliminary results indicated that the depletion of nucleotides
and the consequent inhibition of DNA, RNA and protein synthesis
might have constituted the primary chain of events leading to
reduced glucose carrier production. In the present thesis, we
also plan to examine whether pure recombinant TNF, like other
chemotherapeutic drugs, exerts any effect on the glucose
transport system of EAT cells.
Our preliminary work on TNF-containing mouse serum (TNS)
indicated that the transplantability of EAT cells was abolished
as soon as 4 hr after exposure to TNS, during which period
membrane leakage began to be observed (Fung et al 1985). Is this
membrane derangement a direct effect of TNF? We have noted that
one aspect of membrane function, that of glucose transport is
adversely affected by TNS (Fung et al 1985). The transport of
other essential biomolecules across the tumour cell membrane also
3 14
warrants scrutiny. The uptake of[ Hl-uridine,[ C]-leucine and
[ 3 H]-methionine in TNF-treated and untreated tumour cells will
therefore be examined.
It has been shown that TNF interacts with normal cells as
well as TNF-resistant and TNF-sensitive tumour cells through a
specific high affinity receptor. There is no apparent
correlation between the susceptibility of the cells to ttie
cytotoxic activity of TNF and the number of TNF receptors or
their binding affinity to TNF (Kull et al 1985 Tsujimoto et al
113
1985 Tsujimoto et al 1986 Baglioni et al 1985 Sugarman et al
1985). A possibility is that while the TNF-sensitive tumour
cells possess an intact tranducing mechanism to process the
external signal in the form of TNF, this mechanism is inoperative
in normal cells or TNF-resistant tumour cells. One approach to
study the mechanism of action of TNF might be to identify the
hypothetical lesion in the tranducing and second messenger
systems. Work in this regard has not been reported although
guinea pig lymphotoxin, which shares 30% sequence homology with
45 2+
TNF (Pennica et al 1984) has been shown to increase Ca uptake
rate in target tumour cells (Okamoto et al 1978). In this
thesis, we have studied the involvement of the divalent cation
45 2+
Ca in mediating the effect of TNF.
EXPERIMENTAL
Male ICR strain of mice, 30 to 35 g body weight, were
used in all experiments. Listeria monocytogenes was cultured in
tryptic soy broth as described in Chapter three Materials and
Methods. Bacteria used for injection were obtained from
overnight cultures. Lipopolysaccharide W (LPS, E, coli, serotype
0127:B8), cytochalasln B, and 2-deoxy-D-glucose were purchased
from Sigma. Lanthanum chloride was the product of BDH. Imethyl-
H]-thymidine (89 Cimmol), [5- H]-uridine (28.4Cimmol), 2-
Deoxy-D-[l- HJ-glucose (16.2Cimmol), L-[methyl- H)-methionine
(89 Cimmol), L-(U- C)-leucine (342 mCimmol), [4(n)~ H]~
cytochalasin B (15.8 Cimmol), and calcium chloride
( CaCl )(1.25 mCimmol) were obtained from Amersham. Pure
recombinant human tumour necrosis factor (rTNF) (5.02 x 10 uml)
was generously supplied by Genentech, Inc. (U.S.A.).
TNF-containing serum (TNS) was produced as described (Ha
4
et al 1985a). Briefly, mice were injected intravenously with 10
Lister la in 0.2 ml saline and challenged intravenously with 25 ug
LPS in 0.2 ml saline 7 days afterwards. Mice were bled from
their subclavian vessels 2 hr after LPS injection. The sera were
pooled, filter-sterilized, heated at 56 C for 30 min and stored
frozen at -20 C until use. control serum was obtained from mice
injected with Listeria and challenged with 0.2 ml saline.
Ehrlich ascites tumour (EAT), Ny Klein cell type, was
cultured in RPMI 1640 medium (Sigma) supplemented with 10% heat-
inactivated fetal calf serum (Gibco), 2 mM L-glutamine, 5 mgrnl
g1ucose, 50 unitsml penicillin and 100 ugml streptomycin and
buffered with 25 mM HEPES and 25 mM NaHCO.
The effect of TNS or rTNF on growth of cultured EAT cells
was assayed. EAT cells suspended to about 2 x 10 cells ml
were incubated in 25-cm culture flasks in the presence of
different preparations: diluted TNS,control serum, rTNF or
medium. The flasks were incubated at 37 C for 48 hr. At
different time intervals during the incubations, aliquots of cell
suspension were removed. Cell viability was assayed by trypan
blue exclusion.
To study transport, 2 x 10 EAT cells ml was incubated
in culture flasks in the presence of rTNF (1.0 x 10 uml) at 37
C for 30 hours while TNS (50 fold dilution) at 37 C for 6 hours.
For studying 2-Deoxy-D-[ H]-glucose uptake, method of
Chan et al (1983) were used. (1985), TNS or rTNF treated EAT
suspension (2 x 10 ml in PBS) were equilibrated to 37 C. At
zero sec, 0.2 ml cell suspension was mixed with 0.2 ml pre-warmed
2-Deoxy-D-[ H)-glucose (1 uciumol) to give final concentrations
of 0.1875 to 1.0 mM. Reaction was stopped after 6 sec by
transferring 0.2 ml of mixture to 1 ml Ice-cold PBS supplemented
with 40 mM 2-Deoxy-D-glucose. Cells were collected by
centrifugation at 15000 g for 10 sec in an Eppendorff 5414
microcentrifuge. The supernatant was removed and the cells were
washed with 1 ml of the same buffer. Cell lysis was accomplished
by the addition of 0.2 ml 0.1% Triton X-100. One ml of Triton X-
toluene scintillant was added and the radioactivity count in a
Beckman LS-7000 liquid scintillant counter. Non-specific-
diffusion was corrected by substracting the uptake in the
presence of 10 uM cytochalasin B (final concentration). The
kinetic parameters Vmax and Km, representing respectively the
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maximal uptake rate and apparent half-saturation constant for the
specific transport process, were determined by direct linear plot
(Eisenthal et al 1974).
Equilibrium binding of cytochalasin B was performed
according to Cuppoletti et al (1981) with minor modifications
7
(Chan et al (1983). For measuring total binding, 10 rTNF
3
treated EAT cells in 1 ml PBS were incubated with 0.04 uCi[ H]-
cytochalasin B for 20 min at room temperature. After the
incubation, the cells were collected by centrifugation at 15000 g
for 20 min. The radioactivities of supernatant and pellet
fractions were determined. Cytochalasin B bound was calculated
as percentage of total. To assess the glucose-reversible binding
of cytochalasin B, total binding in the absence and presence of
500 mM D-glucose were measured and the difference obtained.
Maximal glucose-sensitive binding (Bo) and the apparent
dissociation constant (Kd) were determined by Scatchard analysis
(Cuppoletti et al 1981).
For measuring nucleoside and amino acid uptakes, rTNF
treated EAT cells were washed and resuspended with fresh complete
6
RPMI 1640 medium to 2 x 10 cells /ml. 0.2 ml cell suspension,
14 3
was mixed with 5 ul L-[U C]-leucine (50 uCi/ml), [methyl- Hl-
3
thymidine (1 mCi/ml), [5- H]-uridine (1 mCi/ml), or 1-[methyl-
3 O
H]'-methionine (1 mCi/ml) at 37 C. The reaction was stopped at
different intervals by removal of medium and rapidly washing the
cells with PBS.
45 2+
For studying[ Ca] uptake, 0.2 ml rTNF treated EAT
45
cell suspension was Incubated with 0.2 ml[ Ca ]C1 (1.25 inCi/
0 2
mmol) at 37 C. The reaction was stopped at different Intervals
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by removal of medium and rapidly washing with ice-cold saline
45 2+
containing 4 MM Lad to displace the Ca bound to the
3
extracellular glycocalyx (Metcalfe et al 1980). The cells were
lysed by adding 0.2 ml of 0.1% Triton X-100. Radioactivity ire
the lysate was counted in a Beckman LS-7000 liquid scintillation
counter.
For measuring leucine, thymidine, and uridine
incorporation, rTNF treated EAT cells were washed and resuspended
6
with fresh complete RPMI 1640 medium to 1 x 10 cells/ ml. 200
ul cell suspension was added Into each well of a 96--well
3
microtiter plate (Nunc) and then mixed with 5 ul (methyl- HI-
3 14
thymidine (1 mCi/ml), (5- Hl-uridine (1 mCi/ml), or 1-(U- CI-
0
leucine (50 uCi/ml). After incubation at 37 C for 2 hours, the
cells were harvested with saline through filters (Titertek cell
harvester filter, Flow Laboratories) by a cell harvester. The
filters were subsequently washed with 5% trichloroacetic acid
(TCA) and absolute methanol. Filters were dried in air and
placed in scintillation vials containing 3 ml Triton X-toluene
sc-int i l lant. The rad coact ivi t ies were measured with a Beckman
LS-7000 liquid scintillation counter. Background absorption of
radioactivity was corrected by addition of radioactive precursors
after incubation and Immediately before the harvest of cells.
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RESULTS
Tumour necrosis serum (TNS) could inhibit growth of
Ehrlich ascites tumour (EAT) cells as assesed by trypan blue
exclusion test (Fig. 9.1). This growth- inhibitory effect of
TNS on EAT cells showed a dose dependent manner. The larger
amount of TNS was added, the higher degree of cell growth
suppression was observed. Although the cell growth suppression
was prominent after a long time incubation, the suppression in
glucose uptake could be detected as early as 6 hours after
incubation (Fig. 9.2). The TNS preparations used in these
studies were still not purified to homogeneity. Therefore, there
remained a possibility that the decrease of growth and glucose
uptake rate in EAT might be induced by contaminants other ti-tart
TNF. An answer to this question was obtained by using highly
purified recombinant human TNF (rTNF) in the study.
The effect of rTNF on the growth of cultured EAT was
performed in order to choose the optimal dose of rTNF and
incubation period for the study of the mechanism by which rTNF
exerts its cytotoxic or cytostatic effect on EAT cells. As
indicated in Fig. 9.3, the optimal dose of rTNF was about 500
fold dilution (i.e. 1.0 x 10 u/ml) and incubated with EAT at 37
C for 30 hours. Because under this incubation schedule, the
earliest detectable alternation in morphology of EAT cell such as
the phenomenon of cells dissociated from each other as compared
with the cluster form in control cells could be observed (Fig.
9.4). This implied that there may be some changes in the
membrane of EAT cells after treated with 1.0 x 10 u/ml rTNF for
30 hours.
To Investigate whether rTNF had a gross effect on
membrane permeability of EAT cells, the transport of( 1-
thymidine,( HJ-uridine,[ H1-methionine, and[ CJ-leucine in
rTNF treated cells were studied. The results in Figs. 9.5 to 9.8
showed that the uptake of[ H1-thymidine,[ HJ-uridine, and( HJ-
methionine were unaffected while the uptake of[ Cl-leucine was
suppressed following exposure of the cells to 500 fold diluted
rTNF (i.e. 1.0 x 10 uml) for 30 hours.
Since ionic imbalance has been hypothesised to be a
possible cause of cell death accompanying membrane derangement.
(Okamoto et al 1978), the effect of rTNF on Ca influx was
examined. Fig. 9.9 showed that 30 hours incubation of 500 fold
diluted rTNF (i.e. 1.0 x 10 uml) significantly increased the
rate of uptake of Ca in EAT cells.
The effect of rTNF on glucose transport kinetics and
cytochalasin B binding of EAT cells was also investigated.
Recombinant TNF inhibited the maximum 2-Deoxy-D-[ HJ-glucose
uptake rate (Vmax) (Table 9.1) and lowered the number of glucose
carrier (Bo) estimated by cytochalasin B binding, in EAT cells.
However, this treatment did not affect the value of Km of uptake
and the Kd of cytochalasin B binding.
The metabolic effects of rTNF on EAT cells were also
examined. Recombinant TNF used at 500 fold dilution (i.e. 1.0 x
10 uml) significantly suppressed the extent of( CJ-leucine
incorporation (Table 9.2). However, the( Hl-thymidlne and( HJ-
uridine incorporation in such treated cells were unaffected.
TIME OF INCUBATION (hrl
Fig. 9.1 Effect of TNS on EAT cell growth in vitro. 2.4 x 10 cells ml of EAT
were seeded in 25 cm culture flasks. Concentration of viable cells in the culture
incubated with 640 fold(), 80 fold (A A), 40 fold() 'diluted TNS, or
control serum(••) at indicated times were assessed. The results are expressed as
the average of three determinations.
TIME (second)
Fig. 9.2 Time course of 2-Deoxy-D-C HJ-glucose
uptake by EAT cells in the presence of 2% control
serum(••), or 2% TNS() for 6 hours. The
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Fig. 9.3 Effect of rTNF on EAT cell growth in vitro. 1.7 x 10J cells ml of EAT
o
were seeded in 25 cm culture flasks. Concentration of viable cells in the culture
incubated with 100 fold (A a), 500 fold(£), 10000 fold() diluted rTNF
(the original rTNF has 5.02 x 10 uml), or medium(••) at indicated times were




Effect of rTNF on the morphology
of EAT cells. EAT were cultured in complete RPMI 1640 medium in the
presence of 500 fold diluted rTNF (1.0x105 u/ml)(Fig.
9.4a) and medium (Fig. 9.4b) for 30 hours.
TIME (min)
Fig. 9.5 Time course of lmethy C- 3HJ-thymidine uptake
EAT cells in the presence of 500 fold diluted rTNF (i.e.
1.0 x 10 uml)(), or medium(••) for 30 hours.
The values are presented as mean+ S.D. of three
determinations.
TIME (min)
Fig. 9.6 Time coarse of r5-3H3-uridine uptake by EAT cells
in the presence of 500 fold diluted rTNF (i.e. 1.0 x 10-
uml)() or medium(••) for 30 hours. The values
are presented as mean+_ S.D. of three determinations.
TIME (min)
Fig. 9.7 Time course of lmethy C-HJ-methionine uptake
by EAT cells in the presence of 500 fold diluted rTNF
(i.e. 1.0 x 105 uml)() or medium(••) for 30
hours. The values are presented as mean+ S.D. of
t-hrpp Hptprmi nati nns.
TIME (min)
Fig. 9.8 Time course of TU- -leucine uptake by EAT cells in the
presence of 500 fold diluted rTNF (i.e. 1.0 x 10 5 uml)(•-•), or
medium() for 30 hours. The values are presented as mean+ S.D. of
three determinations.
TIME (min)
Fig. 9.9 Time course of C 4Ca]2+ uptake by EAT cells in the
presence of 500 fold diluted rTNF (i.e. 1.0 x 10 uml)(),
or medium(••) for 30 hours. The values are presented as
mean+ S.D. of three determinations.
Table 9.1 Effect of human rTNF on glucose transDort in Ehrlich ascites tumour
Treatment 2-Deoxy-D-glucose uptake Cytochalasin 3 bindinc












- 2 x 10 cellsml of cultured EAT cells were incubated with 500 fold
diluted rTNF (i.e. 1.0 x 10D uml) in medium for 30 hours. After
washing the cells with PBS, 2-Deoxy-D-glucose uptake and cytochalasin
B binding were determined as described in Experimental in this
chapter.
- The values are expressed as mean+ S.D. of two
determinations.
The difference is determined by Student's t-test
for pc0.05
for p -0. 005









2.0 x 10 cells ml of cultured EAT cells were
incubated with 500 fold diluted rTNF (i.e. 1.0 x 10u
ml) in medium for 30 hours. After washing the cells
once with fresh complete RPMI 1640 medium, leucine,
thymidine, and uridine incorporation were determined
as described in Experimental in this chapter.
of incorporation is defined as
incorporation after rTNF treatment
incorporation after medium treatment
100
The values are expressed as mean+ S.D. of six determi¬
nations.
The difference is determined by Student's t-test
for p CO. 0005
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DISCUSSION
It has been reported that TNF causes necrosis of certain
tumours in vivo and regresses various kinds of tumour cells in
vitro (Carswell et al 1975 Helson et al 1975 Matthews et al
1978b Matthews 1981b Ruff et al 1981b). Although a number of
studies have explored the mode of action of TNF (Rubin et al
1985b Scheurich et al 1986 Ruff et al 1981b), the biochemical
mechanism are as yet unclear. In studies in vivo, TNF has been
demonstrated to modulate numerous immunological functions in mice
(Hoffmann et al 1978), to induce the production of natural killer
cells (Chun et al 1979) and to enhance the natural cytotoxicity
of lymphoid cells (Pasanen 1979). Therefore, TNF might both
exert direct cytotoxic effect and modulate immune mechanism to
kill tumour cells in vivo. Nevertheless, it is quite clear from
in vita o studies that TNF must exert a direct cytotoxic action on
the tumour cells. Recently, the availability of highly purified
recombinant human TNF facilitates the studies of
linmunotherapeutic potential and the mechanism of action of TNF.
For in vitro studies,among the cell lines thus far
examined for their vulnerability to TNF (Ha et al 1985a), Ehrlich
ascites tumour (EAT) is the most sensitive as compared with mouse
L-929 cells, which have been reported to be a very sensitive cell
line (Carswell et al 1975). In view of its high susceptibility
to TNF, cultured EAT cells provide an ideal target cell line for
studying the mechanism of TNF action. The effect of rTNF on the
transport system of cultured EAT cells has been studied in the
present investigation.
Because the growth of EAT cells depends primarily on
132
glucose (Lazo 1981) and deprivation of glucose inhibits the
growth of such cells in vitro (Kaminskas et al 1978), glucose
transport in EAT cells is a good index to study the action of
TNF. It was found that TNF could inhibit the glucose transport
of EAT cells (Table 9.1). There was a significantly decrease in
maximum velocity (Vmax) of glucose uptake and the number of
glucose carriers (Bo). However, there was no change in Km and Kd
values. These results showed that inhibition of glucose
transport was due to a change in carrier number rather than
carrier structure and competition between TNF and glucose for the
putative glucose carriers. Table 9.2 and Fig. 9.8 showed that
rTNF could inhibit leucine uptake and incorporation in EAT. This
may imply that protein synthesis might be suppressed and that
this inhibition of protein synthesis might have constituted the
primary chain of events leading to reduce glucose carrier
production. However, the observed decreased glucose carriers
might be also due to the inhibition of translocation of glucose
carriers from intracellular pools to -plasma membrane and/or
enhancement of carrier inactivation. The suppre-ssion of glucose
uptake inhibited the growth of EAT so that the cells might be
arrested In some stages of cell cycle with considerable long
period, which might increase cell sensitivity towards the
cytotoxic effect of TNF (Darzynkiewicz et al 1984). The ability
of highly purified rTNF to suppress glucose uptake in EAT cells
(Table 9.1) confirmed the results Indicated in Fig. 9.2 and those
reported by Fung et al (1985) that the suppression of glucose
uptake was mainly due to TNF rather than the contaminant present
in TNF-containing serum.
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EAT cells from cultures treated with rTNF did not show
any changes in thymidine, and uridine incorporation (Table 9.2)
and uptake rate as compared with those of control EAT cells (Fig.
9.5 and Fig. 9.6), suggesting that neither DNA nor RNA synthesis
are not affected by TNF. These results were consistent with those
reported by Darzynkiewicz et al (1984) and Ruff et al (1981a)
that DNA and RNA are not the primary targets of TNF.
Change in morphology of cultured EAT cells was observed
5
(Fig. 9.4) after exposure to 1.0 x 10 u/ml rTNF for 30 hours.
The result was supported by that EAT cells treated with this
45 2+
dilution of rTNF showed a greater rate of t Cal uptake than
that of untreated cells (Fig. 9.9). However, the transport of
the amino acid methionine was not affected by TNF (Fig. 9.7).
These observations, together with the fact that EAT cells were
still capable of excluding trypan blue would indicate that TNF
caused no overall gross damage to the EAT cell membrane Its
effect on transmembrane transport is a selective one.
Calcium ion is involved in a wide variety of important
cellular process including proliferation (Balk 1971) and membrane
transport (Clausen et al 1975). Hence, in a healthy cell,
optimal concentrations of calcium are required for a number of
intracellular metabolic pathways, -and cell would-be destroyed
when the regulatory system of intracellular calcium were
sufficiently damaged. It has been reported that intracellular
accumulation of calcium led to cytotoxic effects (Metcalfe et al
1980). Thus, the enhanced calcium uptake by EAT cells might
partially account for the tumouricidal activity of TNF. However,
it is not clear whether the increased uptake of calcium ion in
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EAT cells during TNF action is the result of increased calcium




According to Carswell et al (1975), production of tumour
necrosis factor (TNF) required two agents. The first one, now
known as the priming agent, is used to activate the reticulo-
endothelial system, specially the macrophages. The second one is
the eliciting agent. As its name implied, eliciting agent
functions to elicit release of TNF into the serum from the
activated TNF production cells. It is known that there are many
available substances that can be used as the priming agent such
as bacillus Camette-Guerin (BCG) (Carswell et al 1975),
Corynebacterium Parvum (C. Parvum) (Green et al 1977), Listeria
monocytogenes (Ha et al 1985a) etc. Among these substances, C.
Parvum is the best candidate because it is safe even to human and
has been accepted as an anti-tumour drug clinically. However, we
found that different strains of C. Parvum had different ability
to activate the TNF producing cells during TNF production. C.
Parvum strain CN 6134 was a better priming agent than C. Parvum
strain 4182 with respect to TNF production. This indicates that
variations in the content of active component in bacteria
strains may affect their abilities for TNF production. This
result is consistent with the findings reported by Lichtenstein
et al (1982) that C. Parvum contained multiple determinants that
independently activated different macrophage subpopulation.
Since the bacteria such as C. Parvum primed animals were
more sensitive to endotoxin (LPS) shock, our interest also
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concentrated on finding active component in C. Parvum in
different preparations extracted by various methods in order to
minimize the endotoxin shock. It was found that pyridine extract
of C. Parvum contained most active components in C. Parvum for
TNF production but less toxic components that caused death to
mice.
Concerning the eliciting agent in the production of TNF,
there has no other available substances that has been reported in
literature which can be used in the place of LPS from E. Coll to
induce TNF release. Injection of LPS into animals caused a
series of biological activities. Some of which were undesired
since they usually resulted in the death of animals. Hence, we
are interesting in dissociating the beneficial effects of LPS
such as its ability to induce TNF release from the pathological
effects such as inflammation, hypoglycaemia and death. Two
methods were applied in the present study. One was to counteract
the inflammatory effect of LPS by using non-steroidal anti-
Inflammatory drugs or counteract the hypoglycaemic effect of LPS
by using mannoheptulose which is a insulin secretion suppressor.
It was found that these drugs could partially protect bacteria--
primed mice against endotoxin shock by restoring the disturbed
homeostasis induced by LPS without affecting the ability of
animals to produce TNF. The protection could be enhanced by the
co-treatment of anti-inflammatory drug plus mannoheptulose
without affecting TNF production. However, this protection was
partial but not complete.
The second method to lower the toxicity of LPS was to
modify the chemical structure of LPS. With the increasing
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knowledge in LPS structure, our interest is focused on the
relationship between chemical structure of LPS and its ability to
induce TNF into the serum of bacteria-primed animals and its
toxic effect to the host. We found that the content of lipid,
and phosphate in LPS were important for expressing its ability to
induce TNF release and the lethality. Both lipid A (diphosphoryl
lipid A)and monophosphoryl lipid A had the ability to induce TNF
release but both were significantly less effective than GPs
molecule. Monophosphoryl lipid A might be a better eliciting
agent than lipid A in the production of TNF since it was less
toxic than lipid A. Polysaccharide component in LPS was not
capable of releasing TNF but was non-toxic to bacteria-primed
animals its function in LPS has been suggested to increase the
half-life, and solubility of GPS (Riethschel et al 1975 Stephen
1981). From our present study, the best eliciting agent in TNF
production may be a modified LPS molecule with monophosphoryl
lipid A attached to the polysaccharide component.
Although the actual mechanism by which TNF exerts its
cytostatic or cytotoxic effects is unknown, we found that pure
recombinant human TNF (rTNF) suppressed the glucose transport in
Ehrlich ascites tumour (EAT) cell which is very sensitive to TNF
action. This suppression is due to the decreased in the surface
density of glucose carriers rather than change in the structure
of the carriers. The suppression of protein synthesis, assessed
by leucine uptake and incorporation, may be the primary chain of
events leaded to the decreased in glucose carriers.
It was known that lymphotoxin which shares 30% homology
in its amino acid sequence with TNF (Pennica et al 1984) exerted
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Its cytotoxic effect by creating the selective ionic imbalance
45 2+
(increased in Ca uptake) between the intracellular and
extracellular environment of the target cell, L-929. In the
45 2+
present study, we found that Ca uptake in EAT cells was
5
increased after incubation of 1.0 x 10 u/ml rTNF for 30 hours.
However, methionine, thymidine and uridine uptake remained
unchanged.
The suppression of glucose transport and enhancement of
calcium uptake by EAT cell after TNF treatment may account for
the mechanism of TNF effect on EAT cells. Whether rTNF has
similar actions on other tumour cells remains to be investigated.
B. Perspective
The killed bacteria filtrate, now known as Coley's
toxin, were the only known systemic therapy for cancer in 1934
(Old 1985). However, with advances in radiotherapy, surgery and
subsequently chemotherapy, clinical interest in Coley's toxin
therapy diminished. Later, it is found that these methods of
treating cancer involve drastic measures. Surgery is disfiguring
while radiotherapy and chemotherapy make the patients feel
extremely weak and debilitated. None of these treatment is
particularly effective on completely curing cancer without
affecting the host. In these connections, immunotherapy which
depends on basic antigenic differences between cancer and normal
cells for its therapeutic effect is of great importance. The
immune attack is directed against only those cells possessing
tumour-associated antigens without affecting the normal cells.




TNF, one of the newly found immune response modifiers
(Carswell et al 1975), causes necrosis of certain transplanted
tumours without any toxic effect on normal tissue in vivo and
regresses various kinds of tumour cells but not to normal cells
in vitro (Carswell et al 1975 Helson et al 1975 Matthews et al
1978b Matthews 1981b Ruff et al 1981b). However, the lack of
pure TNF hampers the study of its mechanism of action and
clinical trials in cancer patients. Recently, the availability
of large amount of recombinant TNF facilitates the study of its
mechanism of action and its potential application in clinical
medicine.
It is known that there appears species various in the
extent of TNF glycosylation. Mouse TNF is a glycoprotein (Green
et al 1976; 1982; Helson et al 1979) while rabbit TNF and human
TNF are probably a protein (Kelker et al 1985; Haranaka et al
1985). In future studies, it will be important to relate these
differences in glycosylation to biological activities, such as
anti-tumour activity and toxicity, and to compare the in vivo and
in vitro activities of glycosylated (non-recombinant) and non-
glycosylated (recombinant) forms of mouse TNF.
In all ways but one, recombinant hum.-in TNF behaves
exactly as non-recombinant human TNF, that is it causes
hemorrhagic necrosis of mouse tumours, shows the same pattern of
cYtotoxic reactivity for mouse and human cells, and has
synergistic cytotoxic activity with interferon (old 1985).
However, lethality in animal due to treatment of recombinant TNF
have been reported (Beutler et al 1985c; Tracey et al 1986).
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Mice injected with non-recombinant sources of TNF show some
ruffling of fur and weight loss without deaths attributable toy
TNF alone (Old 1985). It is therefore remained to examine
whether the lethal effect of recombinant TNF is simply a mater of
dosage, or whether the presence of toxic impurities or other
factors produced during cloning and expression of cDNA for TNF
(Old 1985).
Recent evidence indicates that human TNF may be identical
to cachectin (Beutler et al 1985c; 1985b; 1986; Tracey et al
1986). Cachectin is a product of macrophages and Is assayed by
its ability to suppress the activity of lipoprotein lipase in
culture adipocytes (Beutler et al 1985d). It has been reported
that beneficial effects conferred by low levels of cachectin
while the lethal effect imparted by high levels of the cachectin
(Beutler et al 1986). Thus, cachectin is the principal mediator
of both endotoxin-induced shock and tumour necrosis. It Is
essential to make efforts to investigate whether human TNF Is
Identical to cachectin before clinical application of human TNF
can widely be used. If it is to be the case, efforts should
focus on modifying the cachectin/ TNF molecule to produce a
modified mediator capable of lysing tumours without undesirable
effects or developing drugs which can anta-gonise the undesirable
effects of cachectin/ TNF.
The synergistic action of TNF and interferon (Williamson
et al 1983) provides strong rationale for their combined use ire
clinical application against tumours. Moreover, combination
therapy with TNF and chemo-therapeutic agents is very effective
against experimental tumours without having detectable side-
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effects, suggesting that chemo-therapeutic agents might expand
therapeutical potential of TNF (Gatanaga et al 1985). Studies on
these synergistic effects should have assistance in elucidating
the mechanism by which TNF exerts its cytotoxic or cytostatic
effect on tumours.
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PHOSPHATE BUFFERED SALINE (PBS)
Ingredien g/ litre mm
NaCl 8.00 140.00
KCl 0.20 2.7C
KH PO 0.20 1.50
2 4
Na HPO 1.15 8.10
a
SCINTILLANT
Triton X- toluene Scintillant
Constituent Quantity
P P 0 12.00 g
POPOP 1.20 g
2.00 1Toluene
1.00 1Triton X-100


